| Symbol | IBRX |
|---|---|
| Name | IMMUNITYBIO, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 3530 JOHN HOPKINS COURT, SAN DIEGO, California, 92121, United States |
| Telephone | +1 858 633-0300 |
| Fax | — |
| — | |
| Website | https://www.immunitybio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001326110 |
| Description | ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The companys immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term immunological memory. Additional info from NASDAQ: |
2026-05-16 02:00
ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX
Read more
2026-05-15 01:53
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines - IBRX
Read more
2026-05-14 18:24
IBRX 12-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims -- Hagens Berman
Read more
2026-05-14 07:23
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Read more
2026-05-14 07:23
ImmunityBio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IBRX
Read more
2026-05-12 19:44
ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Read more
2026-05-12 13:00
Lost Money on ImmunityBio, Inc. (IBRX)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
Read more
2026-05-11 16:50
IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman
Read more
2026-05-09 02:00
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Read more
2026-05-08 20:49
ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06956547 | Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Mainten… | — | Lymphopenia | Available | — | — | ClinicalTrials.gov |
| NCT06810141 | ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in… | — | NMIBC | Available | — | — | ClinicalTrials.gov |
| NCT07578558 | NAI for Sepsis With Persistent Lymphopenia | Phase2 | Sepsis | Not_Yet_Recruiting | 2026-07-06 | 2027-10-04 | ClinicalTrials.gov |
| NCT07488884 | Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept,… | Phase1 | Pancreatic Cancer Resectable | Not_Yet_Recruiting | 2026-06-01 | 2029-06-01 | ClinicalTrials.gov |
| NCT07524257 | Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard… | Phase3 | NSCLC (Advanced Non-small Cell Lung Cancer) | Not_Yet_Recruiting | 2026-05-29 | 2029-12-30 | ClinicalTrials.gov |
| NCT07551544 | ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Expo… | Phase3 | NMIBC | Not_Yet_Recruiting | 2026-05-15 | 2032-05-01 | ClinicalTrials.gov |
| NCT07492875 | Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults W… | Phase3 | Community-Acquired Pneumonia (CAP) | Withdrawn | 2026-04-15 | 2029-12-31 | ClinicalTrials.gov |
| NCT07492888 | Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Seve… | Phase2 | Acute Respiratory Distress Syndrome | Withdrawn | 2026-04-15 | 2027-01-15 | ClinicalTrials.gov |
| NCT07477366 | Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-H… | Phase2 | Relapsed B-Cell Non-Hodgkin Lymphoma | Not_Yet_Recruiting | 2026-04-01 | 2028-12-01 | ClinicalTrials.gov |
| NCT07355205 | First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) i… | Phase2 | Non-small Cell Lung Cancer Stage IV | Not_Yet_Recruiting | 2026-03-31 | 2032-03-31 | ClinicalTrials.gov |
| NCT07217496 | N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of… | Phase1 | Metastatic Urothelial Carcinoma | Withdrawn | 2026-02-15 | 2027-05-30 | ClinicalTrials.gov |
| NCT07049432 | N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or … | Phase1 | B-cell Non Hodgkin Lymphoma | Withdrawn | 2026-02-01 | 2031-12-01 | ClinicalTrials.gov |
| NCT06765902 | Immunotherapy Before and After Surgery | Phase2 | High-risk Prostate Cancer | Withdrawn | 2025-12-15 | 2031-06-30 | ClinicalTrials.gov |
| NCT06765954 | Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation fo… | Phase2 | High-risk Prostate Cancer | Withdrawn | 2025-12-01 | 2031-06-30 | ClinicalTrials.gov |
| NCT07108036 | A Study to Assess Anktiva in Patients With Long Covid-19. | Phase2 | Long COVID | Recruiting | 2025-11-14 | 2026-10-01 | ClinicalTrials.gov |
| NCT07125872 | Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma | Phase2 | Relapsed B-Cell Non Hodgkin Lymphoma | Recruiting | 2025-11-11 | 2028-05-25 | ClinicalTrials.gov |
| NCT06829823 | Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-M… | Phase2 | Non-muscle Invasive Bladder Cancer (NMIBC) | Not_Yet_Recruiting | 2025-11-01 | 2029-11-01 | ClinicalTrials.gov |
| NCT06800963 | ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants … | Phase1 | NMIBC | Recruiting | 2025-10-15 | 2028-02-01 | ClinicalTrials.gov |
| NCT06745908 | Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inh… | Phase3 | NSCLC Stage IV | Recruiting | 2025-10-01 | 2029-01-01 | ClinicalTrials.gov |
| NCT07123727 | A Study to Examine Anktiva for the Treatment of COVID-19. | Phase2 | Long COVID | Recruiting | 2025-09-04 | 2026-07-01 | ClinicalTrials.gov |
| NCT05618925 | Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma | Phase1 | Non Hodgkin's Lymphoma Refractory/Relapsed | Recruiting | 2025-08-22 | 2027-03-15 | ClinicalTrials.gov |
| NCT07556757 | A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymph… | Phase1 | B-ALL | Recruiting | 2025-04-11 | 2028-12-01 | ClinicalTrials.gov |
| NCT06710288 | A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Ther… | Phase2 | Platinum-resistant Ovarian Cancer | Recruiting | 2024-11-06 | 2027-05-01 | ClinicalTrials.gov |
| NCT06334991 | Study for Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma | Phase1 | Non-Hodgkin Lymphoma Refractory/ Relapsed | Recruiting | 2024-08-23 | 2028-03-01 | ClinicalTrials.gov |
| NCT06061809 | N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive G… | Phase2 | Glioblastoma | Recruiting | 2024-08-07 | 2030-12-31 | ClinicalTrials.gov |
| NCT05976828 | IBRX-042 In Participants With HPV-Associated Tumors | Phase1 | HPV-Related Carcinoma | Active_Not_Recruiting | 2024-06-14 | 2033-08-14 | ClinicalTrials.gov |
| NCT06239220 | PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC | Phase2 | Head and Neck Cancer | Recruiting | 2024-02-16 | 2027-01-31 | ClinicalTrials.gov |
| NCT06040918 | Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferatio… | Phase1 | Healthy Subjects | Completed | 2023-10-04 | 2024-09-03 | ClinicalTrials.gov |
| NCT05981131 | Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladd… | — | Non Muscle Invasive Bladder Cancer | Active_Not_Recruiting | 2023-08-17 | 2033-08-30 | ClinicalTrials.gov |
| NCT05304936 | HCW9218 for Advanced Pancreatic Cancer | Phase1 | Advanced Pancreatic Carcinoma | Completed | 2022-10-17 | 2025-02-15 | ClinicalTrials.gov |
| NCT05370040 | THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines | Phase1 | COVID-19 | Terminated | 2022-05-05 | 2024-03-11 | ClinicalTrials.gov |
| NCT04845191 | COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to E… | Phase1 | Covid19 | Withdrawn | 2021-12-01 | 2021-12-14 | ClinicalTrials.gov |
| NCT04843722 | COVID-19 Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who H… | Phase1 | Covid19 | Withdrawn | 2021-12-01 | 2021-12-14 | ClinicalTrials.gov |
| NCT04927884 | A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negativ… | Phase1 | Advanced Triple Negative Breast Cancer | Terminated | 2021-09-08 | 2022-12-12 | ClinicalTrials.gov |
| NCT04898543 | QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Me… | Phase1 | Metastatic Solid Tumor | Active_Not_Recruiting | 2021-06-21 | 2026-05-31 | ClinicalTrials.gov |
| NCT04340596 | Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Witho… | Phase1 | HIV Infection | Active_Not_Recruiting | 2021-05-21 | 2026-12-30 | ClinicalTrials.gov |
| NCT04710303 | COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Plat… | Phase1 | Covid19 | Completed | 2021-03-02 | 2022-08-02 | ClinicalTrials.gov |
| NCT04732468 | COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-De… | Phase1 | Covid19 | Terminated | 2021-02-24 | 2023-01-09 | ClinicalTrials.gov |
| NCT06022224 | A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCI… | Phase2 | COVID-19 | Terminated | 2020-12-09 | 2023-07-19 | ClinicalTrials.gov |
| NCT04591717 | COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVI… | Phase1 | COVID-19 | Completed | 2020-10-19 | 2023-01-18 | ClinicalTrials.gov |
| NCT04397796 | Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With … | Phase1 | COVID | Terminated | 2020-08-03 | 2020-09-06 | ClinicalTrials.gov |
| NCT04385849 | Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-… | Phase1 | COVID-19 | Terminated | 2020-07-22 | 2020-07-25 | ClinicalTrials.gov |
| NCT04390399 | Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of… | Phase2 | Pancreatic Cancer | Active_Not_Recruiting | 2020-07-21 | 2026-05-31 | ClinicalTrials.gov |
| NCT03853317 | QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell C… | Phase2 | Merkel Cell Carcinoma | Terminated | 2020-02-19 | 2022-09-19 | ClinicalTrials.gov |
| NCT04052061 | QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma | Phase1 | Diffuse Large B Cell Lymphoma | Withdrawn | 2019-09-16 | 2022-08-19 | ClinicalTrials.gov |
| NCT04050709 | QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid… | Phase1 | Locally Advanced Solid Tumor | Completed | 2019-07-18 | 2026-03-25 | ClinicalTrials.gov |
| NCT03228667 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previo… | Phase2 | Non-Small Cell Lung Cancer | Active_Not_Recruiting | 2018-12-11 | 2030-12-31 | ClinicalTrials.gov |
| NCT03563157 | QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine | Phase1 | Colorectal Cancer Metastatic | Terminated | 2018-09-28 | 2019-08-21 | ClinicalTrials.gov |
| NCT03554109 | QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine | Phase2 | Triple Negative Breast Cancer (TNBC) | Withdrawn | 2018-09-01 | 2022-02-09 | ClinicalTrials.gov |
| NCT03647423 | QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Ch… | Phase1 | Chordoma | Withdrawn | 2018-08-31 | 2021-12-28 | ClinicalTrials.gov |
| NCT03169777 | QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in… | Phase1 | Colorectal Cancer | Withdrawn | 2018-08-01 | 2021-12-28 | ClinicalTrials.gov |
| NCT03563144 | QUILT-3.088: NANT Pancreatic Cancer Vaccine | Phase2 | Metastatic Pancreatic Cancer | Withdrawn | 2018-08-01 | 2022-02-09 | ClinicalTrials.gov |
| NCT03586869 | QUILT-3.080: NANT Pancreatic Cancer Vaccine | Phase1 | Pancreatic Cancer | Terminated | 2018-07-17 | 2019-08-01 | ClinicalTrials.gov |
| NCT03574649 | QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT … | Phase2 | Non Small Cell Lung Cancer | Withdrawn | 2018-06-01 | 2018-08-22 | ClinicalTrials.gov |
| NCT03563170 | QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine | Phase1 | Hepatocellular Carcinoma Non-resectable | Withdrawn | 2018-05-25 | 2019-08-23 | ClinicalTrials.gov |
| NCT03520686 | Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer | Phase3 | Non Small Cell Lung Cancer | Terminated | 2018-05-18 | 2025-10-13 | ClinicalTrials.gov |
| NCT03387085 | QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Inf… | Phase1 | Triple Negative Breast Cancer | Terminated | 2018-03-19 | 2024-01-16 | ClinicalTrials.gov |
| NCT03169738 | QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immun… | Phase1 | Non-small Cell Lung Cancer | Withdrawn | 2018-02-01 | 2021-12-28 | ClinicalTrials.gov |
| NCT03387111 | QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who … | Phase1 | Squamous Cell Carcinoma | Terminated | 2018-01-09 | 2021-01-11 | ClinicalTrials.gov |
| NCT03387098 | QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have… | Phase1 | Pancreatic Cancer | Terminated | 2017-12-28 | 2019-01-15 | ClinicalTrials.gov |
| NCT03167164 | QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherap… | Phase1 | Merkel Cell Carcinoma | Withdrawn | 2017-12-01 | 2021-12-28 | ClinicalTrials.gov |
| NCT03169764 | QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combin… | Phase1 | Head and Neck Squamous Cell Carcinoma | Withdrawn | 2017-12-01 | 2021-12-28 | ClinicalTrials.gov |
| NCT03169790 | QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy… | Phase1 | Non Hodgkin Lymphoma | Withdrawn | 2017-12-01 | 2021-12-23 | ClinicalTrials.gov |
| NCT03197584 | QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects… | Phase1 | Ovarian Cancer | Withdrawn | 2017-12-01 | 2021-12-28 | ClinicalTrials.gov |
| NCT03197571 | QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subje… | Phase1 | Urothelial Carcinoma | Withdrawn | 2017-12-01 | 2021-12-28 | ClinicalTrials.gov |
| NCT03175666 | QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Imm… | Phase1 | Triple Negative Breast Cancer | Withdrawn | 2017-12-01 | 2021-12-28 | ClinicalTrials.gov |
| NCT03167177 | QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With … | Phase1 | Melanoma | Withdrawn | 2017-12-01 | 2021-12-28 | ClinicalTrials.gov |
| NCT03329248 | QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Im… | Phase1 | Pancreatic Cancer | Terminated | 2017-11-06 | 2019-11-01 | ClinicalTrials.gov |
| NCT03136406 | QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subje… | Phase1 | Pancreatic Cancer | Terminated | 2017-08-11 | 2019-11-01 | ClinicalTrials.gov |
| NCT03027128 | QUILT-3.028: Study of haNK™ for Infusion in Subjects With Metastatic or Locally… | Phase1 | Solid Tumor | Completed | 2017-08-02 | 2019-05-06 | ClinicalTrials.gov |
| NCT03022825 | QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Gue… | Phase2 | Bladder Cancer | Active_Not_Recruiting | 2017-06-02 | 2029-03-01 | ClinicalTrials.gov |
| NCT02782546 | Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Dono… | Phase2 | Acute Myeloid Leukemia | Active_Not_Recruiting | 2017-01-30 | 2028-02-13 | ClinicalTrials.gov |
| NCT02465957 | QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma… | Phase2 | Stage IIIB Merkel Cell Carcinoma | Terminated | 2015-09-24 | 2018-03-19 | ClinicalTrials.gov |
| NCT02200757 | Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Met… | Phase2 | Metastatic Small Cell Lung Cancer | Completed | 2015-04-20 | 2017-05-15 | ClinicalTrials.gov |
| NCT02235701 | Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/M… | Phase1 | Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma | Completed | 2014-09-02 | 2018-05-01 | ClinicalTrials.gov |
| NCT01898793 | Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (… | Phase1 | Leukemia, Myeloid, Acute | Terminated | 2014-08-11 | 2022-04-04 | ClinicalTrials.gov |
| NCT02235688 | Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine … | Phase1 | Metastatic Solid Tumors | Completed | 2014-08-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT02138734 | A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Mu… | Phase1 | Non-muscle Invasive Bladder Cancer | Active_Not_Recruiting | 2014-07-21 | 2039-03-04 | ClinicalTrials.gov |
| NCT00900809 | QUILT-3.018: Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Ac… | Phase1 | Acute Myeloid Leukemia | Completed | 2014-05-12 | 2015-06-02 | ClinicalTrials.gov |
| NCT02029430 | A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sar… | Phase2 | Kaposi's Sarcoma | Completed | 2014-04-03 | 2016-04-25 | ClinicalTrials.gov |
| NCT02014844 | Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjec… | Phase2 | Glioblastoma | Completed | 2014-03-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02049905 | Phase 3 Study to Treat Patients With Soft Tissue Sarcomas | Phase3 | Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma | Completed | 2014-01-01 | 2017-05-01 | ClinicalTrials.gov |
| NCT01706835 | Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH… | Phase1 | Advanced Solid Tumors | Completed | 2012-10-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01673438 | Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxoru… | Phase1 | Advanced Solid Tumor | Completed | 2012-07-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01580397 | Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-… | Phase2 | Pancreatic Ductal Adenocarcinoma | Completed | 2012-05-16 | 2013-07-02 | ClinicalTrials.gov |
| NCT01514188 | Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced… | Phase2 | Metastatic Soft Tissue Sarcoma | Completed | 2012-01-11 | 2014-12-15 | ClinicalTrials.gov |
| NCT01337505 | Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Adva… | Phase1 | Malignant Solid Tumour | Completed | 2011-04-01 | 2012-12-01 | ClinicalTrials.gov |
Total clinical trials: 87
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| rMBCG | Other | Preclinical | NMIBC | AVAILABLE | NCT06810141 |
| rMBCG | Other | Preclinical | NMIBC | AVAILABLE | NCT06810141 |
| rMBCG | Other | Preclinical | NMIBC | AVAILABLE | NCT06810141 |
| rMBCG | Other | Preclinical | NMIBC | AVAILABLE | NCT06810141 |
| rMBCG | Other | Preclinical | NMIBC | AVAILABLE | NCT06810141 |
| rMBCG | Other | Preclinical | NMIBC | AVAILABLE | NCT06810141 |
| Anktiva | Other | Phase PHASE2 | Long COVID | RECRUITING | NCT07123727 |
| rMBCG | Other | Preclinical | NMIBC | AVAILABLE | NCT06810141 |
| Anktiva | Other | Phase PHASE2 | Long COVID | RECRUITING | NCT07123727 |
| rMBCG | Other | Preclinical | NMIBC | AVAILABLE | NCT06810141 |
| Anktiva | Other | Phase PHASE2 | Long COVID | RECRUITING | NCT07123727 |
| Anktiva | Other | Phase PHASE2 | Long COVID | RECRUITING | NCT07123727 |
| Anktiva | Other | Phase PHASE2 | Long COVID | RECRUITING | NCT07123727 |
| Anktiva | Other | Phase PHASE2 | Long COVID | RECRUITING | NCT07123727 |
| N-803 (IL-15 Superagonist) | Other | Phase PHASE2 | Long COVID | RECRUITING | NCT07108036 |
| Standard of Care (SOC) | Other | Phase PHASE2 | Sepsis | NOT_YET_RECRUITING | NCT07578558 |
| Nogapendekin alfa inbakicept (NAI) | Other | Phase PHASE2 | Sepsis | NOT_YET_RECRUITING | NCT07578558 |
| N-803 (IL-15 Superagonist) | Other | Phase PHASE2 | Long COVID | RECRUITING | NCT07108036 |
| Standard of Care (SOC) | Other | Phase PHASE2 | Sepsis | NOT_YET_RECRUITING | NCT07578558 |
| Nogapendekin alfa inbakicept (NAI) | Other | Phase PHASE2 | Sepsis | NOT_YET_RECRUITING | NCT07578558 |
| N-803 (IL-15 Superagonist) | Other | Phase PHASE2 | Long COVID | RECRUITING | NCT07108036 |
| Standard of Care (SOC) | Other | Phase PHASE2 | Sepsis | NOT_YET_RECRUITING | NCT07578558 |
| Nogapendekin alfa inbakicept (NAI) | Other | Phase PHASE2 | Sepsis | NOT_YET_RECRUITING | NCT07578558 |
| N-803 (IL-15 Superagonist) | Other | Phase PHASE2 | Long COVID | RECRUITING | NCT07108036 |
| Standard of Care (SOC) | Other | Phase PHASE2 | Sepsis | NOT_YET_RECRUITING | NCT07578558 |
| Nogapendekin alfa inbakicept (NAI) | Other | Phase PHASE2 | Sepsis | NOT_YET_RECRUITING | NCT07578558 |
| N-803 (IL-15 Superagonist) | Other | Phase PHASE2 | Long COVID | RECRUITING | NCT07108036 |
| Standard of Care (SOC) | Other | Phase PHASE2 | Sepsis | NOT_YET_RECRUITING | NCT07578558 |
| Nogapendekin alfa inbakicept (NAI) | Other | Phase PHASE2 | Sepsis | NOT_YET_RECRUITING | NCT07578558 |
| N-803 (IL-15 Superagonist) | Other | Phase PHASE2 | Long COVID | RECRUITING | NCT07108036 |
| Standard of Care (SOC) | Other | Phase PHASE2 | Sepsis | NOT_YET_RECRUITING | NCT07578558 |
| Nogapendekin alfa inbakicept (NAI) | Other | Phase PHASE2 | Sepsis | NOT_YET_RECRUITING | NCT07578558 |
| Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797) | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome | WITHDRAWN | NCT07492888 |
| Nogapendekin Alfa-Inbakicept (NAI) | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome | WITHDRAWN | NCT07492888 |
| agenT-797 | Other | Phase PHASE3 | Community-Acquired Pneumonia (CAP) | WITHDRAWN | NCT07492875 |
| Nogapendekin alfa inbakicept (NAI) | Other | Phase PHASE3 | Community-Acquired Pneumonia (CAP) | WITHDRAWN | NCT07492875 |
| Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797) | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome | WITHDRAWN | NCT07492888 |
| Nogapendekin Alfa-Inbakicept (NAI) | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome | WITHDRAWN | NCT07492888 |
| agenT-797 | Other | Phase PHASE3 | Community-Acquired Pneumonia (CAP) | WITHDRAWN | NCT07492875 |
| Nogapendekin alfa inbakicept (NAI) | Other | Phase PHASE3 | Community-Acquired Pneumonia (CAP) | WITHDRAWN | NCT07492875 |
| Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797) | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome | WITHDRAWN | NCT07492888 |
| Nogapendekin Alfa-Inbakicept (NAI) | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome | WITHDRAWN | NCT07492888 |
| agenT-797 | Other | Phase PHASE3 | Community-Acquired Pneumonia (CAP) | WITHDRAWN | NCT07492875 |
| Nogapendekin alfa inbakicept (NAI) | Other | Phase PHASE3 | Community-Acquired Pneumonia (CAP) | WITHDRAWN | NCT07492875 |
| Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797) | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome | WITHDRAWN | NCT07492888 |
| Nogapendekin Alfa-Inbakicept (NAI) | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome | WITHDRAWN | NCT07492888 |
| agenT-797 | Other | Phase PHASE3 | Community-Acquired Pneumonia (CAP) | WITHDRAWN | NCT07492875 |
| Nogapendekin alfa inbakicept (NAI) | Other | Phase PHASE3 | Community-Acquired Pneumonia (CAP) | WITHDRAWN | NCT07492875 |
| agenT-797 | Other | Phase PHASE3 | Community-Acquired Pneumonia (CAP) | WITHDRAWN | NCT07492875 |
| Nogapendekin alfa inbakicept (NAI) | Other | Phase PHASE3 | Community-Acquired Pneumonia (CAP) | WITHDRAWN | NCT07492875 |
| M-CENK | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| ETBX-071 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| N-803 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| Post-radiation immunotherapy | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| Androgen Deprivation Therapy (ADT) | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| External Beam Radiation Therapy (EBRT) | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| M-CENK (Activated NK Cells) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| ETBX-071 (PSA-based Oncolytic Virus) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| N-803 (IL-15 Superagonist) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Post-radiation immunotherapy | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| Androgen Deprivation Therapy (ADT) | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| External Beam Radiation Therapy (EBRT) | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| M-CENK (Activated NK Cells) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| ETBX-071 (PSA-based Oncolytic Virus) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| N-803 (IL-15 Superagonist) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| M-CENK | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| ETBX-071 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| N-803 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| Post-radiation immunotherapy | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| Androgen Deprivation Therapy (ADT) | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| External Beam Radiation Therapy (EBRT) | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| M-CENK (Activated NK Cells) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| ETBX-071 (PSA-based Oncolytic Virus) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| N-803 (IL-15 Superagonist) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| M-CENK | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| ETBX-071 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| N-803 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| Post-radiation immunotherapy | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| Androgen Deprivation Therapy (ADT) | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| External Beam Radiation Therapy (EBRT) | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| M-CENK (Activated NK Cells) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| ETBX-071 (PSA-based Oncolytic Virus) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| N-803 (IL-15 Superagonist) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| M-CENK | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| ETBX-071 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| N-803 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| Post-radiation immunotherapy | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| Androgen Deprivation Therapy (ADT) | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| External Beam Radiation Therapy (EBRT) | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| M-CENK (Activated NK Cells) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| ETBX-071 (PSA-based Oncolytic Virus) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| N-803 (IL-15 Superagonist) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| M-CENK | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| ETBX-071 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| N-803 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| Post-radiation immunotherapy | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| Androgen Deprivation Therapy (ADT) | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| External Beam Radiation Therapy (EBRT) | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| M-CENK (Activated NK Cells) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| ETBX-071 (PSA-based Oncolytic Virus) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| N-803 (IL-15 Superagonist) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| M-CENK | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| ETBX-071 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| N-803 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| Post-radiation immunotherapy | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| Androgen Deprivation Therapy (ADT) | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| External Beam Radiation Therapy (EBRT) | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| M-CENK (Activated NK Cells) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| ETBX-071 (PSA-based Oncolytic Virus) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| N-803 (IL-15 Superagonist) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| M-CENK | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| ETBX-071 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| N-803 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| Post-radiation immunotherapy | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| Androgen Deprivation Therapy (ADT) | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| External Beam Radiation Therapy (EBRT) | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| M-CENK (Activated NK Cells) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| ETBX-071 (PSA-based Oncolytic Virus) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| N-803 (IL-15 Superagonist) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| M-CENK | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| ETBX-071 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| N-803 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| Post-radiation immunotherapy | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| Androgen Deprivation Therapy (ADT) | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| External Beam Radiation Therapy (EBRT) | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| M-CENK (Activated NK Cells) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| ETBX-071 (PSA-based Oncolytic Virus) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| N-803 (IL-15 Superagonist) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| M-CENK | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| ETBX-071 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| N-803 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| Post-radiation immunotherapy | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| Androgen Deprivation Therapy (ADT) | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| External Beam Radiation Therapy (EBRT) | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| M-CENK (Activated NK Cells) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| ETBX-071 (PSA-based Oncolytic Virus) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| N-803 (IL-15 Superagonist) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| M-CENK | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| ETBX-071 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| N-803 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| Post-radiation immunotherapy | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| Androgen Deprivation Therapy (ADT) | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| External Beam Radiation Therapy (EBRT) | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| M-CENK (Activated NK Cells) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| ETBX-071 (PSA-based Oncolytic Virus) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| N-803 (IL-15 Superagonist) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| CD19 t-haNK- IV Administration | Other | Phase PHASE2 | Relapsed B-Cell Non Hodgkin Lymphoma | RECRUITING | NCT07125872 |
| CD19 t-haNK | Other | Phase PHASE1 | Non-Hodgkin Lymphoma Refractory/ Relapsed | RECRUITING | NCT06334991 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Pemetrexed (nonsquamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Nab-paclitaxel OR Paclitaxel OR Docetaxel (squamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Nab-paclitaxel (squamous) OR Pemetrexed (nonsquamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Cisplatin or Carboplatin | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Pembrolizumab | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Drug: Nogapendekin alfa inbakicept (NAI) | Drug | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| M-CENK | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| ETBX-071 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| N-803 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| Post-radiation immunotherapy | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| Androgen Deprivation Therapy (ADT) | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| External Beam Radiation Therapy (EBRT) | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| M-CENK (Activated NK Cells) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| ETBX-071 (PSA-based Oncolytic Virus) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| N-803 (IL-15 Superagonist) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| CD19 t-haNK- IV Administration | Other | Phase PHASE2 | Relapsed B-Cell Non Hodgkin Lymphoma | RECRUITING | NCT07125872 |
| CD19 t-haNK | Other | Phase PHASE1 | Non-Hodgkin Lymphoma Refractory/ Relapsed | RECRUITING | NCT06334991 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Pemetrexed (nonsquamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Nab-paclitaxel OR Paclitaxel OR Docetaxel (squamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Nab-paclitaxel (squamous) OR Pemetrexed (nonsquamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Cisplatin or Carboplatin | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Pembrolizumab | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Drug: Nogapendekin alfa inbakicept (NAI) | Drug | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| M-CENK | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| ETBX-071 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| N-803 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| Post-radiation immunotherapy | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| Androgen Deprivation Therapy (ADT) | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| External Beam Radiation Therapy (EBRT) | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| M-CENK (Activated NK Cells) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| ETBX-071 (PSA-based Oncolytic Virus) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| N-803 (IL-15 Superagonist) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| CD19 t-haNK- IV Administration | Other | Phase PHASE2 | Relapsed B-Cell Non Hodgkin Lymphoma | RECRUITING | NCT07125872 |
| CD19 t-haNK | Other | Phase PHASE1 | Non-Hodgkin Lymphoma Refractory/ Relapsed | RECRUITING | NCT06334991 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Pemetrexed (nonsquamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Nab-paclitaxel OR Paclitaxel OR Docetaxel (squamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Nab-paclitaxel (squamous) OR Pemetrexed (nonsquamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Cisplatin or Carboplatin | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Pembrolizumab | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Drug: Nogapendekin alfa inbakicept (NAI) | Drug | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| M-CENK | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| ETBX-071 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| N-803 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| Pemetrexed (nonsquamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Nab-paclitaxel OR Paclitaxel OR Docetaxel (squamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Nab-paclitaxel (squamous) OR Pemetrexed (nonsquamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Cisplatin or Carboplatin | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Pembrolizumab | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Drug: Nogapendekin alfa inbakicept (NAI) | Drug | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| M-CENK | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| ETBX-071 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| N-803 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| CD19 t-haNK | Other | Phase PHASE1 | Non-Hodgkin Lymphoma Refractory/ Relapsed | RECRUITING | NCT06334991 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Pemetrexed (nonsquamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Nab-paclitaxel OR Paclitaxel OR Docetaxel (squamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Nab-paclitaxel (squamous) OR Pemetrexed (nonsquamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Cisplatin or Carboplatin | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Pembrolizumab | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Drug: Nogapendekin alfa inbakicept (NAI) | Drug | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| M-CENK | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| ETBX-071 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| N-803 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| Pemetrexed (nonsquamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Nab-paclitaxel OR Paclitaxel OR Docetaxel (squamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Nab-paclitaxel (squamous) OR Pemetrexed (nonsquamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Cisplatin or Carboplatin | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Pembrolizumab | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Drug: Nogapendekin alfa inbakicept (NAI) | Drug | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| M-CENK | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| ETBX-071 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| N-803 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| Post-radiation immunotherapy | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| Androgen Deprivation Therapy (ADT) | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| External Beam Radiation Therapy (EBRT) | Drug | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| M-CENK (Activated NK Cells) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| ETBX-071 (PSA-based Oncolytic Virus) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| N-803 (IL-15 Superagonist) | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765954 |
| CD19 t-haNK- IV Administration | Other | Phase PHASE2 | Relapsed B-Cell Non Hodgkin Lymphoma | RECRUITING | NCT07125872 |
| CD19 t-haNK | Other | Phase PHASE1 | Non-Hodgkin Lymphoma Refractory/ Relapsed | RECRUITING | NCT06334991 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Pemetrexed (nonsquamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Nab-paclitaxel OR Paclitaxel OR Docetaxel (squamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Nab-paclitaxel (squamous) OR Pemetrexed (nonsquamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Cisplatin or Carboplatin | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Pembrolizumab | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Drug: Nogapendekin alfa inbakicept (NAI) | Drug | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| M-CENK | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| ETBX-071 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| N-803 | Other | Phase PHASE2 | High-risk Prostate Cancer | WITHDRAWN | NCT06765902 |
| Pemetrexed (nonsquamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Nab-paclitaxel OR Paclitaxel OR Docetaxel (squamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Nab-paclitaxel (squamous) OR Pemetrexed (nonsquamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Cisplatin or Carboplatin | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Pembrolizumab | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Drug: Nogapendekin alfa inbakicept (NAI) | Drug | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| CD19 t-haNK | Other | Phase PHASE1 | Non-Hodgkin Lymphoma Refractory/ Relapsed | RECRUITING | NCT06334991 |
| CD19 t-haNK- IV Administration | Other | Phase PHASE2 | Relapsed B-Cell Non Hodgkin Lymphoma | RECRUITING | NCT07125872 |
| Pemetrexed (nonsquamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Nab-paclitaxel OR Paclitaxel OR Docetaxel (squamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Nab-paclitaxel (squamous) OR Pemetrexed (nonsquamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Cisplatin or Carboplatin | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Pembrolizumab | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Drug: Nogapendekin alfa inbakicept (NAI) | Drug | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| CD19 t-haNK | Other | Phase PHASE1 | Non-Hodgkin Lymphoma Refractory/ Relapsed | RECRUITING | NCT06334991 |
| CD19 t-haNK- IV Administration | Other | Phase PHASE2 | Relapsed B-Cell Non Hodgkin Lymphoma | RECRUITING | NCT07125872 |
| Pemetrexed (nonsquamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Nab-paclitaxel OR Paclitaxel OR Docetaxel (squamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Nab-paclitaxel (squamous) OR Pemetrexed (nonsquamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Cisplatin or Carboplatin | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Pembrolizumab | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Drug: Nogapendekin alfa inbakicept (NAI) | Drug | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| CD19 t-haNK | Other | Phase PHASE1 | Non-Hodgkin Lymphoma Refractory/ Relapsed | RECRUITING | NCT06334991 |
| CD19 t-haNK- IV Administration | Other | Phase PHASE2 | Relapsed B-Cell Non Hodgkin Lymphoma | RECRUITING | NCT07125872 |
| Pemetrexed (nonsquamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Nab-paclitaxel OR Paclitaxel OR Docetaxel (squamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Nab-paclitaxel (squamous) OR Pemetrexed (nonsquamous) | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Cisplatin or Carboplatin | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Pembrolizumab | Other | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| Drug: Nogapendekin alfa inbakicept (NAI) | Drug | Phase PHASE3 | NSCLC (Advanced Non-small Cell Lung Cancer) | NOT_YET_RECRUITING | NCT07524257 |
| CD19 t-haNK | Other | Phase PHASE1 | Non-Hodgkin Lymphoma Refractory/ Relapsed | RECRUITING | NCT06334991 |
| CD19 t-haNK- IV Administration | Other | Phase PHASE2 | Relapsed B-Cell Non Hodgkin Lymphoma | RECRUITING | NCT07125872 |
| N-803 | Other | Phase PHASE1 | Hepatocellular Carcinoma Non-resectable | WITHDRAWN | NCT03563170 |
| Cetuximab | Other | Phase PHASE1 | Hepatocellular Carcinoma Non-resectable | WITHDRAWN | NCT03563170 |
| GI-6301 | Other | Phase PHASE1 | Hepatocellular Carcinoma Non-resectable | WITHDRAWN | NCT03563170 |
| GI-6207 | Other | Phase PHASE1 | Hepatocellular Carcinoma Non-resectable | WITHDRAWN | NCT03563170 |
| ETBX-061 | Other | Phase PHASE1 | Hepatocellular Carcinoma Non-resectable | WITHDRAWN | NCT03563170 |
| ETBX-051 | Other | Phase PHASE1 | Hepatocellular Carcinoma Non-resectable | WITHDRAWN | NCT03563170 |
| Aldoxorubicin hydrochloride | Other | Phase PHASE1 | Hepatocellular Carcinoma Non-resectable | WITHDRAWN | NCT03563170 |
| SBRT | Other | Phase PHASE1 | Hepatocellular Carcinoma Non-resectable | WITHDRAWN | NCT03563170 |
| Sorafenib | Other | Phase PHASE1 | Hepatocellular Carcinoma Non-resectable | WITHDRAWN | NCT03563170 |
| nab-Paclitaxel | Other | Phase PHASE1 | Hepatocellular Carcinoma Non-resectable | WITHDRAWN | NCT03563170 |
| Leucovorin | Other | Phase PHASE1 | Hepatocellular Carcinoma Non-resectable | WITHDRAWN | NCT03563170 |
| 5-Fluorouracil | Other | Phase PHASE1 | Hepatocellular Carcinoma Non-resectable | WITHDRAWN | NCT03563170 |
| Cyclophosphamide | Other | Phase PHASE1 | Hepatocellular Carcinoma Non-resectable | WITHDRAWN | NCT03563170 |
| Capecitabine | Other | Phase PHASE1 | Hepatocellular Carcinoma Non-resectable | WITHDRAWN | NCT03563170 |
| avelumab | Other | Phase PHASE1 | Hepatocellular Carcinoma Non-resectable | WITHDRAWN | NCT03563170 |
| haNK for infusion | Other | Phase PHASE1 | Hepatocellular Carcinoma Non-resectable | WITHDRAWN | NCT03563170 |
| GI-4000 | Other | Phase PHASE1 | Hepatocellular Carcinoma Non-resectable | WITHDRAWN | NCT03563170 |
| ETBX-011 | Other | Phase PHASE1 | Hepatocellular Carcinoma Non-resectable | WITHDRAWN | NCT03563170 |
| gemcitabine | Other | Phase PHASE1 | Metastatic Solid Tumors | COMPLETED | NCT02235688 |
| aldoxorubicin | Other | Phase PHASE1 | Metastatic Solid Tumors | COMPLETED | NCT02235688 |
| aldoxorubicin | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01706835 |
| aldoxorubicin | Other | Phase PHASE1 | Advanced Solid Tumor | COMPLETED | NCT01673438 |
| INNO-206 | Other | Phase PHASE1 | Malignant Solid Tumour | COMPLETED | NCT01337505 |
| hAd5-S-Fusion+N-ETSD vaccine | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT04591717 |
| Bone marrow for correlative studies | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | TERMINATED | NCT01898793 |
| Peripheral blood for correlative studies | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | TERMINATED | NCT01898793 |
| ALT-803 | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | TERMINATED | NCT01898793 |
| IL-2 | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | TERMINATED | NCT01898793 |
| Cytokine-induced killer cells | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | TERMINATED | NCT01898793 |
| Leukapheresis | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | TERMINATED | NCT01898793 |
| Cyclophosphamide | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | TERMINATED | NCT01898793 |
| Fludarabine | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | TERMINATED | NCT01898793 |
| aNK (NK-92) + N-803 | Other | Phase PHASE2 | Stage IIIB Merkel Cell Carcinoma | TERMINATED | NCT02465957 |
| aNK (NK-92) | Other | Phase PHASE2 | Stage IIIB Merkel Cell Carcinoma | TERMINATED | NCT02465957 |
| SBRT | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03387098 |
| Oxaliplatin | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03387098 |
| lovaza | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03387098 |
| nab-Paclitaxel | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03387098 |
| Leucovorin | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03387098 |
| Fluorouracil | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03387098 |
| Cyclophosphamide | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03387098 |
| Capecitabine | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03387098 |
| bevacizumab | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03387098 |
| avelumab | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03387098 |
| haNK for infusion | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03387098 |
| GI-4000 | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03387098 |
| ETBX-011 | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03387098 |
| ALT-803 | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03387098 |
| Aldoxorubicin HCl | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03387098 |
| 250 mg/m2 aldoxorubicin | Other | Phase PHASE1 | Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma | COMPLETED | NCT02235701 |
| 170 mg/m2 aldoxorubicin | Other | Phase PHASE1 | Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma | COMPLETED | NCT02235701 |
| 350 mg/m2 aldoxorubicin | Other | Phase PHASE2 | Glioblastoma | COMPLETED | NCT02014844 |
| 250 mg/m2 aldoxorubicin | Other | Phase PHASE2 | Glioblastoma | COMPLETED | NCT02014844 |
| Doxorubicin | Other | Phase PHASE2 | Metastatic Soft Tissue Sarcoma | COMPLETED | NCT01514188 |
| INNO-206 | Other | Phase PHASE2 | Metastatic Soft Tissue Sarcoma | COMPLETED | NCT01514188 |
| INNO-206 | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma | COMPLETED | NCT01580397 |
| Placebo (0.9% (w/v) saline) | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT06022224 |
| hAd5-S-Fusion+N-ETSD | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT06022224 |
| GI-4000 | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03136406 |
| ETBX-011 | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03136406 |
| aNK for Infusion | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03136406 |
| ALT-803 | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03136406 |
| avelumab | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03136406 |
| bevacizumab | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03136406 |
| nab-paclitaxel | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03136406 |
| Leucovorin | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03136406 |
| 5-Fluorouracil | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03136406 |
| Capecitabine | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03136406 |
| Oxaliplatin | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03136406 |
| Cyclophosphamide | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03136406 |
| 150 mg/m2 aldoxorubicin | Other | Phase PHASE2 | Kaposi's Sarcoma | COMPLETED | NCT02029430 |
| 100 mg/m2 aldoxorubicin | Other | Phase PHASE2 | Kaposi's Sarcoma | COMPLETED | NCT02029430 |
| 50 mg/m2 aldoxorubicin | Other | Phase PHASE2 | Kaposi's Sarcoma | COMPLETED | NCT02029430 |
| Cyclophosphamide | Other | Phase PHASE1 | Advanced Triple Negative Breast Cancer | TERMINATED | NCT04927884 |
| Sacituzumab Govitecan-Hziy | Other | Phase PHASE1 | Advanced Triple Negative Breast Cancer | TERMINATED | NCT04927884 |
| PD-L1 t-haNK | Other | Phase PHASE1 | Advanced Triple Negative Breast Cancer | TERMINATED | NCT04927884 |
| N-803 | Other | Phase PHASE1 | Advanced Triple Negative Breast Cancer | TERMINATED | NCT04927884 |
| Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide) | Drug | Phase PHASE3 | Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma | COMPLETED | NCT02049905 |
| Aldoxorubicin | Other | Phase PHASE3 | Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma | COMPLETED | NCT02049905 |
| Topotecan | Other | Phase PHASE2 | Metastatic Small Cell Lung Cancer | COMPLETED | NCT02200757 |
| Aldoxorubicin | Other | Phase PHASE2 | Metastatic Small Cell Lung Cancer | COMPLETED | NCT02200757 |
| N-803 | Other | Phase PHASE1 | Squamous Cell Carcinoma | TERMINATED | NCT03387111 |
| SBRT | Other | Phase PHASE1 | Squamous Cell Carcinoma | TERMINATED | NCT03387111 |
| Necitumumab | Other | Phase PHASE1 | Squamous Cell Carcinoma | TERMINATED | NCT03387111 |
| nab-Paclitaxel | Other | Phase PHASE1 | Squamous Cell Carcinoma | TERMINATED | NCT03387111 |
| Leucovorin | Other | Phase PHASE1 | Squamous Cell Carcinoma | TERMINATED | NCT03387111 |
| Fluorouracil | Other | Phase PHASE1 | Squamous Cell Carcinoma | TERMINATED | NCT03387111 |
| Cyclophosphamide | Other | Phase PHASE1 | Squamous Cell Carcinoma | TERMINATED | NCT03387111 |
| Cisplatin | Other | Phase PHASE1 | Squamous Cell Carcinoma | TERMINATED | NCT03387111 |
| Cetuximab | Other | Phase PHASE1 | Squamous Cell Carcinoma | TERMINATED | NCT03387111 |
| Capecitabine | Other | Phase PHASE1 | Squamous Cell Carcinoma | TERMINATED | NCT03387111 |
| bevacizumab | Other | Phase PHASE1 | Squamous Cell Carcinoma | TERMINATED | NCT03387111 |
| Avelumab | Other | Phase PHASE1 | Squamous Cell Carcinoma | TERMINATED | NCT03387111 |
| haNK for infusion | Other | Phase PHASE1 | Squamous Cell Carcinoma | TERMINATED | NCT03387111 |
| GI-6301 | Other | Phase PHASE1 | Squamous Cell Carcinoma | TERMINATED | NCT03387111 |
| GI-6207 | Other | Phase PHASE1 | Squamous Cell Carcinoma | TERMINATED | NCT03387111 |
| GI-4000 | Other | Phase PHASE1 | Squamous Cell Carcinoma | TERMINATED | NCT03387111 |
| ETBX-061 | Other | Phase PHASE1 | Squamous Cell Carcinoma | TERMINATED | NCT03387111 |
| ETBX-051 | Other | Phase PHASE1 | Squamous Cell Carcinoma | TERMINATED | NCT03387111 |
| ETBX-021 | Other | Phase PHASE1 | Squamous Cell Carcinoma | TERMINATED | NCT03387111 |
| ETBX-011 | Other | Phase PHASE1 | Squamous Cell Carcinoma | TERMINATED | NCT03387111 |
| Aldoxorubicin HCl | Other | Phase PHASE1 | Squamous Cell Carcinoma | TERMINATED | NCT03387111 |
| haNK™ | Other | Phase PHASE2 | Merkel Cell Carcinoma | TERMINATED | NCT03853317 |
| N-803 | Other | Phase PHASE2 | Merkel Cell Carcinoma | TERMINATED | NCT03853317 |
| Avelumab | Other | Phase PHASE2 | Merkel Cell Carcinoma | TERMINATED | NCT03853317 |
| SBRT | Other | Phase PHASE1 | Triple Negative Breast Cancer | TERMINATED | NCT03387085 |
| nab-Paclitaxel | Other | Phase PHASE1 | Triple Negative Breast Cancer | TERMINATED | NCT03387085 |
| Leucovorin | Other | Phase PHASE1 | Triple Negative Breast Cancer | TERMINATED | NCT03387085 |
| 5-Fluorouracil | Other | Phase PHASE1 | Triple Negative Breast Cancer | TERMINATED | NCT03387085 |
| Cyclophosphamide | Other | Phase PHASE1 | Triple Negative Breast Cancer | TERMINATED | NCT03387085 |
| Cisplatin | Other | Phase PHASE1 | Triple Negative Breast Cancer | TERMINATED | NCT03387085 |
| Capecitabine | Other | Phase PHASE1 | Triple Negative Breast Cancer | TERMINATED | NCT03387085 |
| bevacizumab | Other | Phase PHASE1 | Triple Negative Breast Cancer | TERMINATED | NCT03387085 |
| avelumab | Other | Phase PHASE1 | Triple Negative Breast Cancer | TERMINATED | NCT03387085 |
| haNK for Infusion | Other | Phase PHASE1 | Triple Negative Breast Cancer | TERMINATED | NCT03387085 |
| GI-6301 | Other | Phase PHASE1 | Triple Negative Breast Cancer | TERMINATED | NCT03387085 |
| GI-6207 | Other | Phase PHASE1 | Triple Negative Breast Cancer | TERMINATED | NCT03387085 |
| GI-4000 | Other | Phase PHASE1 | Triple Negative Breast Cancer | TERMINATED | NCT03387085 |
| ETBX-061 | Other | Phase PHASE1 | Triple Negative Breast Cancer | TERMINATED | NCT03387085 |
| ETBX-051 | Other | Phase PHASE1 | Triple Negative Breast Cancer | TERMINATED | NCT03387085 |
| ETBX-011 | Other | Phase PHASE1 | Triple Negative Breast Cancer | TERMINATED | NCT03387085 |
| N-803 | Other | Phase PHASE1 | Triple Negative Breast Cancer | TERMINATED | NCT03387085 |
| Aldoxorubicin HCl | Other | Phase PHASE1 | Triple Negative Breast Cancer | TERMINATED | NCT03387085 |
| SBRT | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03586869 |
| Avelumab | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03586869 |
| Oxaliplatin | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03586869 |
| nab-Paclitaxel | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03586869 |
| Leucovorin | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03586869 |
| Fluorouracil | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03586869 |
| Cyclophosphamide | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03586869 |
| Capecitabine | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03586869 |
| bevacizumab | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03586869 |
| haNK for infusion | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03586869 |
| GI-6301 | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03586869 |
| GI-6207 | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03586869 |
| GI-4000 | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03586869 |
| ETBX-061 | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03586869 |
| ETBX-051 | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03586869 |
| ETBX-021 | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03586869 |
| ETBX-011 | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03586869 |
| ALT-803 | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03586869 |
| Aldoxorubicin HCl | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03586869 |
| Placebo | Other | Phase PHASE1 | COVID | TERMINATED | NCT04397796 |
| BM-Allo.MSC | Other | Phase PHASE1 | COVID | TERMINATED | NCT04397796 |
| Saline | Other | Phase PHASE1 | COVID-19 | TERMINATED | NCT04385849 |
| N-803 | Other | Phase PHASE1 | COVID-19 | TERMINATED | NCT04385849 |
| hAd5-SFusion+ N-ETSD (Oral capsule) | Other | Phase PHASE1 | Covid19 | TERMINATED | NCT04732468 |
| hAd5-S-Fusion+N-ETSD (Suspension for injection) | Other | Phase PHASE1 | Covid19 | TERMINATED | NCT04732468 |
| hAd5-S-Fusion+N-ETSD vaccine | Other | Phase PHASE1 | Covid19 | COMPLETED | NCT04710303 |
| haNK™ for Infusion | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT03027128 |
| SBRT | Other | Phase PHASE1 | Colorectal Cancer Metastatic | TERMINATED | NCT03563157 |
| Regorafenib | Other | Phase PHASE1 | Colorectal Cancer Metastatic | TERMINATED | NCT03563157 |
| Oxaliplatin | Other | Phase PHASE1 | Colorectal Cancer Metastatic | TERMINATED | NCT03563157 |
| Nab-paclitaxel | Other | Phase PHASE1 | Colorectal Cancer Metastatic | TERMINATED | NCT03563157 |
| Leucovorin | Other | Phase PHASE1 | Colorectal Cancer Metastatic | TERMINATED | NCT03563157 |
| 5-Fluorouracil | Other | Phase PHASE1 | Colorectal Cancer Metastatic | TERMINATED | NCT03563157 |
| Cyclophosphamide | Other | Phase PHASE1 | Colorectal Cancer Metastatic | TERMINATED | NCT03563157 |
| Cetuximab | Other | Phase PHASE1 | Colorectal Cancer Metastatic | TERMINATED | NCT03563157 |
| Capecitabine | Other | Phase PHASE1 | Colorectal Cancer Metastatic | TERMINATED | NCT03563157 |
| Avelumab | Other | Phase PHASE1 | Colorectal Cancer Metastatic | TERMINATED | NCT03563157 |
| haNK | Other | Phase PHASE1 | Colorectal Cancer Metastatic | TERMINATED | NCT03563157 |
| GI-6301 | Other | Phase PHASE1 | Colorectal Cancer Metastatic | TERMINATED | NCT03563157 |
| GI-6207 | Other | Phase PHASE1 | Colorectal Cancer Metastatic | TERMINATED | NCT03563157 |
| GI-4000 | Other | Phase PHASE1 | Colorectal Cancer Metastatic | TERMINATED | NCT03563157 |
| ETBX-061 | Other | Phase PHASE1 | Colorectal Cancer Metastatic | TERMINATED | NCT03563157 |
| ETBX-051 | Other | Phase PHASE1 | Colorectal Cancer Metastatic | TERMINATED | NCT03563157 |
| ETBX-021 | Other | Phase PHASE1 | Colorectal Cancer Metastatic | TERMINATED | NCT03563157 |
| ETBX-011 | Other | Phase PHASE1 | Colorectal Cancer Metastatic | TERMINATED | NCT03563157 |
| ALT-803 | Other | Phase PHASE1 | Colorectal Cancer Metastatic | TERMINATED | NCT03563157 |
| Aldoxorubicin Hydrochloride | Other | Phase PHASE1 | Colorectal Cancer Metastatic | TERMINATED | NCT03563157 |
| SBRT | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03329248 |
| Oxaliplatin | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03329248 |
| lovaza | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03329248 |
| nab-Paclitaxel | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03329248 |
| Leucovorin | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03329248 |
| Fluorouracil | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03329248 |
| Cyclophosphamide | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03329248 |
| Capecitabine | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03329248 |
| bevacizumab | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03329248 |
| avelumab | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03329248 |
| haNK for infusion | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03329248 |
| GI-4000 | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03329248 |
| ETBX-011 | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03329248 |
| ALT-803 | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03329248 |
| hAd5-S-Fusion+N-ETSD vaccine | Other | Phase PHASE1 | Covid19 | WITHDRAWN | NCT04845191 |
| hAd5-S-Fusion+N-ETSD vaccine | Other | Phase PHASE1 | Covid19 | WITHDRAWN | NCT04843722 |
| CD19 t-haNK | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma | WITHDRAWN | NCT04052061 |
| SBRT | Other | Phase PHASE1 | Chordoma | WITHDRAWN | NCT03647423 |
| Cyclophosphamide | Other | Phase PHASE1 | Chordoma | WITHDRAWN | NCT03647423 |
| Cetuximab | Other | Phase PHASE1 | Chordoma | WITHDRAWN | NCT03647423 |
| Avelumab | Other | Phase PHASE1 | Chordoma | WITHDRAWN | NCT03647423 |
| haNK | Other | Phase PHASE1 | Chordoma | WITHDRAWN | NCT03647423 |
| GI-6301 | Other | Phase PHASE1 | Chordoma | WITHDRAWN | NCT03647423 |
| ETBX-061 | Other | Phase PHASE1 | Chordoma | WITHDRAWN | NCT03647423 |
| ETBX-051 | Other | Phase PHASE1 | Chordoma | WITHDRAWN | NCT03647423 |
| ALT-803 | Other | Phase PHASE1 | Chordoma | WITHDRAWN | NCT03647423 |
| Aldoxorubicin Hydrochloride | Other | Phase PHASE1 | Chordoma | WITHDRAWN | NCT03647423 |
| carboplatin | Other | Phase PHASE2 | Non Small Cell Lung Cancer | WITHDRAWN | NCT03574649 |
| Docetaxel | Other | Phase PHASE2 | Non Small Cell Lung Cancer | WITHDRAWN | NCT03574649 |
| haNK | Other | Phase PHASE2 | Non Small Cell Lung Cancer | WITHDRAWN | NCT03574649 |
| ALT-803 | Other | Phase PHASE2 | Non Small Cell Lung Cancer | WITHDRAWN | NCT03574649 |
| Avelumab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | WITHDRAWN | NCT03574649 |
| Aldoxorubicin | Other | Phase PHASE2 | Non Small Cell Lung Cancer | WITHDRAWN | NCT03574649 |
| GI-6301 | Other | Phase PHASE2 | Non Small Cell Lung Cancer | WITHDRAWN | NCT03574649 |
| GI-4000 | Other | Phase PHASE2 | Non Small Cell Lung Cancer | WITHDRAWN | NCT03574649 |
| ETBX-061 | Other | Phase PHASE2 | Non Small Cell Lung Cancer | WITHDRAWN | NCT03574649 |
| ETBX-051 | Other | Phase PHASE2 | Non Small Cell Lung Cancer | WITHDRAWN | NCT03574649 |
| ETBX-011 | Other | Phase PHASE2 | Non Small Cell Lung Cancer | WITHDRAWN | NCT03574649 |
| Cyclophosphamide | Other | Phase PHASE2 | Non Small Cell Lung Cancer | WITHDRAWN | NCT03574649 |
| 5Fluorouracil | Other | Phase PHASE2 | Non Small Cell Lung Cancer | WITHDRAWN | NCT03574649 |
| Cisplatin | Other | Phase PHASE2 | Non Small Cell Lung Cancer | WITHDRAWN | NCT03574649 |
| Nab-paclitaxel | Other | Phase PHASE2 | Non Small Cell Lung Cancer | WITHDRAWN | NCT03574649 |
| Oxaliplatin | Other | Phase PHASE2 | Metastatic Pancreatic Cancer | WITHDRAWN | NCT03563144 |
| Leucovorin | Other | Phase PHASE2 | Metastatic Pancreatic Cancer | WITHDRAWN | NCT03563144 |
| 5-Fluorouracil | Other | Phase PHASE2 | Metastatic Pancreatic Cancer | WITHDRAWN | NCT03563144 |
| Cyclophosphamide | Other | Phase PHASE2 | Metastatic Pancreatic Cancer | WITHDRAWN | NCT03563144 |
| Capecitabine | Other | Phase PHASE2 | Metastatic Pancreatic Cancer | WITHDRAWN | NCT03563144 |
| Bevacizumab | Other | Phase PHASE2 | Metastatic Pancreatic Cancer | WITHDRAWN | NCT03563144 |
| Avelumab | Other | Phase PHASE2 | Metastatic Pancreatic Cancer | WITHDRAWN | NCT03563144 |
| haNK | Other | Phase PHASE2 | Metastatic Pancreatic Cancer | WITHDRAWN | NCT03563144 |
| GI-6301 | Other | Phase PHASE2 | Metastatic Pancreatic Cancer | WITHDRAWN | NCT03563144 |
| GI-6207 | Other | Phase PHASE2 | Metastatic Pancreatic Cancer | WITHDRAWN | NCT03563144 |
| GI-4000 | Other | Phase PHASE2 | Metastatic Pancreatic Cancer | WITHDRAWN | NCT03563144 |
| ETBX-061 | Other | Phase PHASE2 | Metastatic Pancreatic Cancer | WITHDRAWN | NCT03563144 |
| ETBX-051 | Other | Phase PHASE2 | Metastatic Pancreatic Cancer | WITHDRAWN | NCT03563144 |
| ETBX-021 | Other | Phase PHASE2 | Metastatic Pancreatic Cancer | WITHDRAWN | NCT03563144 |
| ETBX-011 | Other | Phase PHASE2 | Metastatic Pancreatic Cancer | WITHDRAWN | NCT03563144 |
| ALT-803 | Other | Phase PHASE2 | Metastatic Pancreatic Cancer | WITHDRAWN | NCT03563144 |
| Aldoxorubicin HCl | Other | Phase PHASE2 | Metastatic Pancreatic Cancer | WITHDRAWN | NCT03563144 |
| Nab-paclitaxel | Other | Phase PHASE2 | Metastatic Pancreatic Cancer | WITHDRAWN | NCT03563144 |
| Gemcitabine | Other | Phase PHASE2 | Metastatic Pancreatic Cancer | WITHDRAWN | NCT03563144 |
| paclitaxel | Other | Phase PHASE2 | Triple Negative Breast Cancer (TNBC) | WITHDRAWN | NCT03554109 |
| Doxorubicin HCL | Other | Phase PHASE2 | Triple Negative Breast Cancer (TNBC) | WITHDRAWN | NCT03554109 |
| Cyclophosphamide | Other | Phase PHASE2 | Triple Negative Breast Cancer (TNBC) | WITHDRAWN | NCT03554109 |
| haNK | Other | Phase PHASE2 | Triple Negative Breast Cancer (TNBC) | WITHDRAWN | NCT03554109 |
| ALT-803 | Other | Phase PHASE2 | Triple Negative Breast Cancer (TNBC) | WITHDRAWN | NCT03554109 |
| Avelumab | Other | Phase PHASE2 | Triple Negative Breast Cancer (TNBC) | WITHDRAWN | NCT03554109 |
| GI-6301 | Other | Phase PHASE2 | Triple Negative Breast Cancer (TNBC) | WITHDRAWN | NCT03554109 |
| GI-6207 | Other | Phase PHASE2 | Triple Negative Breast Cancer (TNBC) | WITHDRAWN | NCT03554109 |
| GI-4000 | Other | Phase PHASE2 | Triple Negative Breast Cancer (TNBC) | WITHDRAWN | NCT03554109 |
| ETBX-061 | Other | Phase PHASE2 | Triple Negative Breast Cancer (TNBC) | WITHDRAWN | NCT03554109 |
| ETBX-051 | Other | Phase PHASE2 | Triple Negative Breast Cancer (TNBC) | WITHDRAWN | NCT03554109 |
| ETBX-011 | Other | Phase PHASE2 | Triple Negative Breast Cancer (TNBC) | WITHDRAWN | NCT03554109 |
| nab-Paclitaxel | Other | Phase PHASE2 | Triple Negative Breast Cancer (TNBC) | WITHDRAWN | NCT03554109 |
| Aldoxorubicin HCl | Other | Phase PHASE2 | Triple Negative Breast Cancer (TNBC) | WITHDRAWN | NCT03554109 |
| 5-Fluorouracil | Other | Phase PHASE2 | Triple Negative Breast Cancer (TNBC) | WITHDRAWN | NCT03554109 |
| Leucovorin | Other | Phase PHASE2 | Triple Negative Breast Cancer (TNBC) | WITHDRAWN | NCT03554109 |
| haNK® | Other | Phase PHASE1 | Ovarian Cancer | WITHDRAWN | NCT03197584 |
| GI-6301 | Other | Phase PHASE1 | Ovarian Cancer | WITHDRAWN | NCT03197584 |
| GI-4000 | Other | Phase PHASE1 | Ovarian Cancer | WITHDRAWN | NCT03197584 |
| ETBX-061 | Other | Phase PHASE1 | Ovarian Cancer | WITHDRAWN | NCT03197584 |
| ETBX-051 | Other | Phase PHASE1 | Ovarian Cancer | WITHDRAWN | NCT03197584 |
| ETBX-021 | Other | Phase PHASE1 | Ovarian Cancer | WITHDRAWN | NCT03197584 |
| ALT-803 | Other | Phase PHASE1 | Ovarian Cancer | WITHDRAWN | NCT03197584 |
| Stereotactic Body Radiation Therapy | Drug | Phase PHASE1 | Ovarian Cancer | WITHDRAWN | NCT03197584 |
| Oxaliplatin | Other | Phase PHASE1 | Ovarian Cancer | WITHDRAWN | NCT03197584 |
| omega-3 acid ethyl esters | Other | Phase PHASE1 | Ovarian Cancer | WITHDRAWN | NCT03197584 |
| Paclitaxel | Other | Phase PHASE1 | Ovarian Cancer | WITHDRAWN | NCT03197584 |
| Leucovorin | Other | Phase PHASE1 | Ovarian Cancer | WITHDRAWN | NCT03197584 |
| Fulvestrant | Other | Phase PHASE1 | Ovarian Cancer | WITHDRAWN | NCT03197584 |
| 5-fluorouracil | Other | Phase PHASE1 | Ovarian Cancer | WITHDRAWN | NCT03197584 |
| Cyclophosphamide | Other | Phase PHASE1 | Ovarian Cancer | WITHDRAWN | NCT03197584 |
| Capecitabine | Other | Phase PHASE1 | Ovarian Cancer | WITHDRAWN | NCT03197584 |
| Bevacizumab | Other | Phase PHASE1 | Ovarian Cancer | WITHDRAWN | NCT03197584 |
| Avelumab | Other | Phase PHASE1 | Ovarian Cancer | WITHDRAWN | NCT03197584 |
| haNK | Other | Phase PHASE1 | Urothelial Carcinoma | WITHDRAWN | NCT03197571 |
| GI-6301 | Other | Phase PHASE1 | Urothelial Carcinoma | WITHDRAWN | NCT03197571 |
| GI-6207 | Other | Phase PHASE1 | Urothelial Carcinoma | WITHDRAWN | NCT03197571 |
| GI-4000 | Other | Phase PHASE1 | Urothelial Carcinoma | WITHDRAWN | NCT03197571 |
| ETBX-061 | Other | Phase PHASE1 | Urothelial Carcinoma | WITHDRAWN | NCT03197571 |
| ETBX-051 | Other | Phase PHASE1 | Urothelial Carcinoma | WITHDRAWN | NCT03197571 |
| ETBX-021 | Other | Phase PHASE1 | Urothelial Carcinoma | WITHDRAWN | NCT03197571 |
| ETBX-011 | Other | Phase PHASE1 | Urothelial Carcinoma | WITHDRAWN | NCT03197571 |
| ALT-803 | Other | Phase PHASE1 | Urothelial Carcinoma | WITHDRAWN | NCT03197571 |
| Stereotactic Body Radiation Therapy | Drug | Phase PHASE1 | Urothelial Carcinoma | WITHDRAWN | NCT03197571 |
| Lovaza | Other | Phase PHASE1 | Urothelial Carcinoma | WITHDRAWN | NCT03197571 |
| nab-paclitaxel | Other | Phase PHASE1 | Urothelial Carcinoma | WITHDRAWN | NCT03197571 |
| leucovorin | Other | Phase PHASE1 | Urothelial Carcinoma | WITHDRAWN | NCT03197571 |
| fulvestrant | Other | Phase PHASE1 | Urothelial Carcinoma | WITHDRAWN | NCT03197571 |
| 5Fluorouracil (5-FU) | Other | Phase PHASE1 | Urothelial Carcinoma | WITHDRAWN | NCT03197571 |
| cyclophosphamide | Other | Phase PHASE1 | Urothelial Carcinoma | WITHDRAWN | NCT03197571 |
| cisplatin | Other | Phase PHASE1 | Urothelial Carcinoma | WITHDRAWN | NCT03197571 |
| capecitabine | Other | Phase PHASE1 | Urothelial Carcinoma | WITHDRAWN | NCT03197571 |
| bevacizumab | Other | Phase PHASE1 | Urothelial Carcinoma | WITHDRAWN | NCT03197571 |
| avelumab | Other | Phase PHASE1 | Urothelial Carcinoma | WITHDRAWN | NCT03197571 |
| haNK | Other | Phase PHASE1 | Triple Negative Breast Cancer | WITHDRAWN | NCT03175666 |
| GI-6301 | Other | Phase PHASE1 | Triple Negative Breast Cancer | WITHDRAWN | NCT03175666 |
| GI-6207 | Other | Phase PHASE1 | Triple Negative Breast Cancer | WITHDRAWN | NCT03175666 |
| GI-4000 | Other | Phase PHASE1 | Triple Negative Breast Cancer | WITHDRAWN | NCT03175666 |
| ETBX-061 | Other | Phase PHASE1 | Triple Negative Breast Cancer | WITHDRAWN | NCT03175666 |
| ETBX-051 | Other | Phase PHASE1 | Triple Negative Breast Cancer | WITHDRAWN | NCT03175666 |
| ETBX-011 | Other | Phase PHASE1 | Triple Negative Breast Cancer | WITHDRAWN | NCT03175666 |
| ALT-803 | Other | Phase PHASE1 | Triple Negative Breast Cancer | WITHDRAWN | NCT03175666 |
| Stereotactic Body Radiation Therapy | Drug | Phase PHASE1 | Triple Negative Breast Cancer | WITHDRAWN | NCT03175666 |
| Lovaza | Other | Phase PHASE1 | Triple Negative Breast Cancer | WITHDRAWN | NCT03175666 |
| nab-paclitaxel | Other | Phase PHASE1 | Triple Negative Breast Cancer | WITHDRAWN | NCT03175666 |
| Leucovorin | Other | Phase PHASE1 | Triple Negative Breast Cancer | WITHDRAWN | NCT03175666 |
| 5-Fluorouracil | Other | Phase PHASE1 | Triple Negative Breast Cancer | WITHDRAWN | NCT03175666 |
| cyclophosphamide | Other | Phase PHASE1 | Triple Negative Breast Cancer | WITHDRAWN | NCT03175666 |
| cisplatin | Other | Phase PHASE1 | Triple Negative Breast Cancer | WITHDRAWN | NCT03175666 |
| capecitabine | Other | Phase PHASE1 | Triple Negative Breast Cancer | WITHDRAWN | NCT03175666 |
| bevacizumab | Other | Phase PHASE1 | Triple Negative Breast Cancer | WITHDRAWN | NCT03175666 |
| avelumab | Other | Phase PHASE1 | Triple Negative Breast Cancer | WITHDRAWN | NCT03175666 |
| haNK | Other | Phase PHASE1 | Colorectal Cancer | WITHDRAWN | NCT03169777 |
| GI-6301 | Other | Phase PHASE1 | Colorectal Cancer | WITHDRAWN | NCT03169777 |
| GI-6207 | Other | Phase PHASE1 | Colorectal Cancer | WITHDRAWN | NCT03169777 |
| GI-4000 | Other | Phase PHASE1 | Colorectal Cancer | WITHDRAWN | NCT03169777 |
| ETBX-061 | Other | Phase PHASE1 | Colorectal Cancer | WITHDRAWN | NCT03169777 |
| ETBX-051 | Other | Phase PHASE1 | Colorectal Cancer | WITHDRAWN | NCT03169777 |
| ETBX-021 | Other | Phase PHASE1 | Colorectal Cancer | WITHDRAWN | NCT03169777 |
| ETBX-011 | Other | Phase PHASE1 | Colorectal Cancer | WITHDRAWN | NCT03169777 |
| ALT-803 | Other | Phase PHASE1 | Colorectal Cancer | WITHDRAWN | NCT03169777 |
| Stereotactic Body Radiation Therapy | Drug | Phase PHASE1 | Colorectal Cancer | WITHDRAWN | NCT03169777 |
| oxaliplatin | Other | Phase PHASE1 | Colorectal Cancer | WITHDRAWN | NCT03169777 |
| Lovaza | Other | Phase PHASE1 | Colorectal Cancer | WITHDRAWN | NCT03169777 |
| nivolumab | Other | Phase PHASE1 | Colorectal Cancer | WITHDRAWN | NCT03169777 |
| nab paclitaxel | Other | Phase PHASE1 | Colorectal Cancer | WITHDRAWN | NCT03169777 |
| leucovorin | Other | Phase PHASE1 | Colorectal Cancer | WITHDRAWN | NCT03169777 |
| fulvestrant | Other | Phase PHASE1 | Colorectal Cancer | WITHDRAWN | NCT03169777 |
| 5-Fluorouracil (5-FU) | Other | Phase PHASE1 | Colorectal Cancer | WITHDRAWN | NCT03169777 |
| Cyclophosphamide | Other | Phase PHASE1 | Colorectal Cancer | WITHDRAWN | NCT03169777 |
| cetuximab | Other | Phase PHASE1 | Colorectal Cancer | WITHDRAWN | NCT03169777 |
| capecitabine | Other | Phase PHASE1 | Colorectal Cancer | WITHDRAWN | NCT03169777 |
| bevacizumab | Other | Phase PHASE1 | Colorectal Cancer | WITHDRAWN | NCT03169777 |
| avelumab | Other | Phase PHASE1 | Colorectal Cancer | WITHDRAWN | NCT03169777 |
| haNK | Other | Phase PHASE1 | Non-small Cell Lung Cancer | WITHDRAWN | NCT03169738 |
| GI-6301 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | WITHDRAWN | NCT03169738 |
| GI-6207 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | WITHDRAWN | NCT03169738 |
| GI-4000 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | WITHDRAWN | NCT03169738 |
| ETBX-061 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | WITHDRAWN | NCT03169738 |
| ETBX-051 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | WITHDRAWN | NCT03169738 |
| ETBX-021 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | WITHDRAWN | NCT03169738 |
| ETBX-011 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | WITHDRAWN | NCT03169738 |
| ALT-803 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | WITHDRAWN | NCT03169738 |
| Stereotactic Body Radiation Therapy | Drug | Phase PHASE1 | Non-small Cell Lung Cancer | WITHDRAWN | NCT03169738 |
| Oxaliplatin | Other | Phase PHASE1 | Non-small Cell Lung Cancer | WITHDRAWN | NCT03169738 |
| Lovaza | Other | Phase PHASE1 | Non-small Cell Lung Cancer | WITHDRAWN | NCT03169738 |
| nivolumab | Other | Phase PHASE1 | Non-small Cell Lung Cancer | WITHDRAWN | NCT03169738 |
| nab paclitaxel | Other | Phase PHASE1 | Non-small Cell Lung Cancer | WITHDRAWN | NCT03169738 |
| leucovorin | Other | Phase PHASE1 | Non-small Cell Lung Cancer | WITHDRAWN | NCT03169738 |
| fulvestrant | Other | Phase PHASE1 | Non-small Cell Lung Cancer | WITHDRAWN | NCT03169738 |
| 5-Fluorouracil (5-FU) | Other | Phase PHASE1 | Non-small Cell Lung Cancer | WITHDRAWN | NCT03169738 |
| cyclophosphamide | Other | Phase PHASE1 | Non-small Cell Lung Cancer | WITHDRAWN | NCT03169738 |
| Cisplatin | Other | Phase PHASE1 | Non-small Cell Lung Cancer | WITHDRAWN | NCT03169738 |
| Capecitabine | Other | Phase PHASE1 | Non-small Cell Lung Cancer | WITHDRAWN | NCT03169738 |
| Bevacizumab | Other | Phase PHASE1 | Non-small Cell Lung Cancer | WITHDRAWN | NCT03169738 |
| avelumab | Other | Phase PHASE1 | Non-small Cell Lung Cancer | WITHDRAWN | NCT03169738 |
| haNK | Other | Phase PHASE1 | Melanoma | WITHDRAWN | NCT03167177 |
| GI-6301 | Other | Phase PHASE1 | Melanoma | WITHDRAWN | NCT03167177 |
| GI-6207 | Other | Phase PHASE1 | Melanoma | WITHDRAWN | NCT03167177 |
| ETBX-061 | Other | Phase PHASE1 | Melanoma | WITHDRAWN | NCT03167177 |
| ETBX-051 | Other | Phase PHASE1 | Melanoma | WITHDRAWN | NCT03167177 |
| ETBX-011 | Other | Phase PHASE1 | Melanoma | WITHDRAWN | NCT03167177 |
| ALT-803 | Other | Phase PHASE1 | Melanoma | WITHDRAWN | NCT03167177 |
| Stereotactic Body Radiation Therapy | Drug | Phase PHASE1 | Melanoma | WITHDRAWN | NCT03167177 |
| omega-3-acid ethyl esters | Other | Phase PHASE1 | Melanoma | WITHDRAWN | NCT03167177 |
| Nivolumab | Other | Phase PHASE1 | Melanoma | WITHDRAWN | NCT03167177 |
| nab-paclitaxel | Other | Phase PHASE1 | Melanoma | WITHDRAWN | NCT03167177 |
| Leucovorin | Other | Phase PHASE1 | Melanoma | WITHDRAWN | NCT03167177 |
| 5-fluorouracil | Other | Phase PHASE1 | Melanoma | WITHDRAWN | NCT03167177 |
| Cyclophosphamide | Other | Phase PHASE1 | Melanoma | WITHDRAWN | NCT03167177 |
| Cisplatin | Other | Phase PHASE1 | Melanoma | WITHDRAWN | NCT03167177 |
| Capecitabine | Other | Phase PHASE1 | Melanoma | WITHDRAWN | NCT03167177 |
| Bevacizumab | Other | Phase PHASE1 | Melanoma | WITHDRAWN | NCT03167177 |
| Avelumab | Other | Phase PHASE1 | Melanoma | WITHDRAWN | NCT03167177 |
| haNK | Other | Phase PHASE1 | Merkel Cell Carcinoma | WITHDRAWN | NCT03167164 |
| GI-6301 | Other | Phase PHASE1 | Merkel Cell Carcinoma | WITHDRAWN | NCT03167164 |
| ETBX-061 | Other | Phase PHASE1 | Merkel Cell Carcinoma | WITHDRAWN | NCT03167164 |
| ETBX-051 | Other | Phase PHASE1 | Merkel Cell Carcinoma | WITHDRAWN | NCT03167164 |
| ALT-803 | Other | Phase PHASE1 | Merkel Cell Carcinoma | WITHDRAWN | NCT03167164 |
| Stereotactic Body Radiation Therapy | Drug | Phase PHASE1 | Merkel Cell Carcinoma | WITHDRAWN | NCT03167164 |
| omega-3-acid ethyl esters | Other | Phase PHASE1 | Merkel Cell Carcinoma | WITHDRAWN | NCT03167164 |
| nab-Paclitaxel | Other | Phase PHASE1 | Merkel Cell Carcinoma | WITHDRAWN | NCT03167164 |
| Leucovorin | Other | Phase PHASE1 | Merkel Cell Carcinoma | WITHDRAWN | NCT03167164 |
| 5-fluorouracil | Other | Phase PHASE1 | Merkel Cell Carcinoma | WITHDRAWN | NCT03167164 |
| Cyclophosphamide | Other | Phase PHASE1 | Merkel Cell Carcinoma | WITHDRAWN | NCT03167164 |
| Cisplatin | Other | Phase PHASE1 | Merkel Cell Carcinoma | WITHDRAWN | NCT03167164 |
| Capecitabine | Other | Phase PHASE1 | Merkel Cell Carcinoma | WITHDRAWN | NCT03167164 |
| Bevacizumab | Other | Phase PHASE1 | Merkel Cell Carcinoma | WITHDRAWN | NCT03167164 |
| Avelumab | Other | Phase PHASE1 | Merkel Cell Carcinoma | WITHDRAWN | NCT03167164 |
| haNK | Other | Phase PHASE1 | Non Hodgkin Lymphoma | WITHDRAWN | NCT03169790 |
| ETBX-061 | Other | Phase PHASE1 | Non Hodgkin Lymphoma | WITHDRAWN | NCT03169790 |
| ALT-803 | Other | Phase PHASE1 | Non Hodgkin Lymphoma | WITHDRAWN | NCT03169790 |
| Stereotactic Body Radiation Therapy | Drug | Phase PHASE1 | Non Hodgkin Lymphoma | WITHDRAWN | NCT03169790 |
| rituximab | Other | Phase PHASE1 | Non Hodgkin Lymphoma | WITHDRAWN | NCT03169790 |
| Oxaliplatin | Other | Phase PHASE1 | Non Hodgkin Lymphoma | WITHDRAWN | NCT03169790 |
| Lovaza | Other | Phase PHASE1 | Non Hodgkin Lymphoma | WITHDRAWN | NCT03169790 |
| nab-paclitaxel | Other | Phase PHASE1 | Non Hodgkin Lymphoma | WITHDRAWN | NCT03169790 |
| leucovorin | Other | Phase PHASE1 | Non Hodgkin Lymphoma | WITHDRAWN | NCT03169790 |
| 5-Fluorouracil (5-FU) | Other | Phase PHASE1 | Non Hodgkin Lymphoma | WITHDRAWN | NCT03169790 |
| cyclophosphamide | Other | Phase PHASE1 | Non Hodgkin Lymphoma | WITHDRAWN | NCT03169790 |
| capecitabine | Other | Phase PHASE1 | Non Hodgkin Lymphoma | WITHDRAWN | NCT03169790 |
| bevacizumab | Other | Phase PHASE1 | Non Hodgkin Lymphoma | WITHDRAWN | NCT03169790 |
| avelumab | Other | Phase PHASE1 | Non Hodgkin Lymphoma | WITHDRAWN | NCT03169790 |
| haNK | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | WITHDRAWN | NCT03169764 |
| GI-6301 | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | WITHDRAWN | NCT03169764 |
| GI-6207 | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | WITHDRAWN | NCT03169764 |
| GI-4000 | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | WITHDRAWN | NCT03169764 |
| ETBX-061 | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | WITHDRAWN | NCT03169764 |
| ETBX-051 | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | WITHDRAWN | NCT03169764 |
| ETBX-021 | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | WITHDRAWN | NCT03169764 |
| ETBX-011 | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | WITHDRAWN | NCT03169764 |
| ALT-803 | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | WITHDRAWN | NCT03169764 |
| Stereotactic Body Radiation Therapy | Drug | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | WITHDRAWN | NCT03169764 |
| Lovaza | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | WITHDRAWN | NCT03169764 |
| nivolumab | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | WITHDRAWN | NCT03169764 |
| nab-paclitaxel | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | WITHDRAWN | NCT03169764 |
| leucovorin | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | WITHDRAWN | NCT03169764 |
| fulvestrant | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | WITHDRAWN | NCT03169764 |
| 5-Fluorouracil (5-FU) | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | WITHDRAWN | NCT03169764 |
| cyclophosphamide | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | WITHDRAWN | NCT03169764 |
| Cisplatin | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | WITHDRAWN | NCT03169764 |
| Cetuximab | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | WITHDRAWN | NCT03169764 |
| Capecitabine | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | WITHDRAWN | NCT03169764 |
| Bevacizumab | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | WITHDRAWN | NCT03169764 |
| Avelumab | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | WITHDRAWN | NCT03169764 |
| EUA or approved vaccine | Other | Phase PHASE1 | COVID-19 | TERMINATED | NCT05370040 |
| AAHI-SC3 Vaccine | Other | Phase PHASE1 | COVID-19 | TERMINATED | NCT05370040 |
| AAHI-SC2 Vaccine | Other | Phase PHASE1 | COVID-19 | TERMINATED | NCT05370040 |
| 10-1074 | Other | Phase PHASE1 | HIV Infection | ACTIVE_NOT_RECRUITING | NCT04340596 |
| VRC07-523LS | Other | Phase PHASE1 | HIV Infection | ACTIVE_NOT_RECRUITING | NCT04340596 |
| N-803 (IL-15 Superagonist) | Other | Phase PHASE1 | HIV Infection | ACTIVE_NOT_RECRUITING | NCT04340596 |
| M-CENK | Other | Phase PHASE2 | High-risk Prostate Cancer | NOT_YET_RECRUITING | NCT06765902 |
| ETBX-071 | Other | Phase PHASE2 | High-risk Prostate Cancer | NOT_YET_RECRUITING | NCT06765902 |
| N-803 | Other | Phase PHASE2 | High-risk Prostate Cancer | NOT_YET_RECRUITING | NCT06765902 |
| Post-radiation immunotherapy | Drug | Phase PHASE2 | High-risk Prostate Cancer | NOT_YET_RECRUITING | NCT06765954 |
| Androgen Deprivation Therapy (ADT) | Drug | Phase PHASE2 | High-risk Prostate Cancer | NOT_YET_RECRUITING | NCT06765954 |
| External Beam Radiation Therapy (EBRT) | Drug | Phase PHASE2 | High-risk Prostate Cancer | NOT_YET_RECRUITING | NCT06765954 |
| M-CENK (Activated NK Cells) | Other | Phase PHASE2 | High-risk Prostate Cancer | NOT_YET_RECRUITING | NCT06765954 |
| ETBX-071 (PSA-based Oncolytic Virus) | Other | Phase PHASE2 | High-risk Prostate Cancer | NOT_YET_RECRUITING | NCT06765954 |
| N-803 (IL-15 Superagonist) | Other | Phase PHASE2 | High-risk Prostate Cancer | NOT_YET_RECRUITING | NCT06765954 |
| NAI | Other | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT06239220 |
| Cetuximab | Other | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT06239220 |
| PD-L1 t-haNK | Other | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT06239220 |
| nogapendekin-alfa inbakicept | Other | Preclinical | Lymphopenia | AVAILABLE | NCT06956547 |
| N-803 | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT06040918 |
| N-803 and Gemcitabine | Other | Phase PHASE2 | Non-muscle Invasive Bladder Cancer (NMIBC) | NOT_YET_RECRUITING | NCT06829823 |
| N-803 and BCG | Other | Phase PHASE2 | Non-muscle Invasive Bladder Cancer (NMIBC) | NOT_YET_RECRUITING | NCT06829823 |
| N-803 | Other | Phase PHASE2 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT03022825 |
| N-803 and BCG | Other | Phase PHASE2 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT03022825 |
| M-CENK | Other | Phase PHASE2 | Platinum-resistant Ovarian Cancer | RECRUITING | NCT06710288 |
| N-803 | Other | Phase PHASE2 | Platinum-resistant Ovarian Cancer | RECRUITING | NCT06710288 |
| Gemcitabine | Other | Phase PHASE2 | Platinum-resistant Ovarian Cancer | RECRUITING | NCT06710288 |
| IBRX-042 | Other | Phase PHASE1 | HPV-Related Carcinoma | ACTIVE_NOT_RECRUITING | NCT05976828 |
| Anktiva | Other | Phase PHASE2 | Long COVID | RECRUITING | NCT07123727 |
| Apheresis collection of MNCs (part A) | Other | Phase PHASE1 | Metastatic Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04898543 |
| N-803 (Cohort 2 part B) | Other | Phase PHASE1 | Metastatic Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04898543 |
| M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B) | Other | Phase PHASE1 | Metastatic Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04898543 |
| Irinotecan liposome | Other | Phase PHASE2 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04390399 |
| SBRT | Other | Phase PHASE2 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04390399 |
| Leucovorin | Other | Phase PHASE2 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04390399 |
| 5-Fluorouracil | Other | Phase PHASE2 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04390399 |
| Cyclophosphamide | Other | Phase PHASE2 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04390399 |
| Gemcitabine | Other | Phase PHASE2 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04390399 |
| Nab-paclitaxel | Other | Phase PHASE2 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04390399 |
| PD-L1 t-haNK | Other | Phase PHASE2 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04390399 |
| Aldoxorubicin HCl | Other | Phase PHASE2 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04390399 |
| N-803 | Other | Phase PHASE2 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04390399 |
| Leukapheresis | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT02782546 |
| ALT-803 | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT02782546 |
| CIML NK cell infusion | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT02782546 |
| G-CSF | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT02782546 |
| Mycophenolate mofetil | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT02782546 |
| Tacrolimus | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT02782546 |
| Graft cell infusion | Other | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT02782546 |
| N-803 + Docetaxel + Nivolumab | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03228667 |
| N-803 + Docetaxel + Pembrolizumab | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03228667 |
| N-803 + Durvalumab + PD-L1 t-haNK | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03228667 |
| N-803 + Avelumab + PD-L1 t-haNK | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03228667 |
| N-803 + Atezolizumab + PD-L1 t-haNK | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03228667 |
| N-803 + Nivolumab + PD-L1 t-haNK | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03228667 |
| N-803 + Pembrolizumab + PD-L1 t-haNK | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03228667 |
| N-803 + Durvalumab | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03228667 |
| N-803 + Avelumab | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03228667 |
| N-803 + Atezolizumab | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03228667 |
| N-803 + Nivolumab | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03228667 |
| N-803 + Pembrolizumab | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03228667 |
| Nogapendekin alfa inbakicept | Other | Phase PHASE2 | Non-small Cell Lung Cancer Stage IV | NOT_YET_RECRUITING | NCT07355205 |
| Nivolumab | Other | Phase PHASE2 | Non-small Cell Lung Cancer Stage IV | NOT_YET_RECRUITING | NCT07355205 |
| Ipilimumab | Other | Phase PHASE2 | Non-small Cell Lung Cancer Stage IV | NOT_YET_RECRUITING | NCT07355205 |
| Tumor Treating Fields (TTFields, 200 kHz) | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT06061809 |
| N-803 | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT06061809 |
| PD-L1 t-haNK | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT06061809 |
| Bevacizumab | Other | Phase PHASE2 | Glioblastoma | RECRUITING | NCT06061809 |
| CD19 t-haNK- IV Administration | Other | Phase PHASE2 | Relapsed B-Cell Non Hodgkin Lymphoma | RECRUITING | NCT07125872 |
| rituximab | Other | Phase PHASE2 | Relapsed B-Cell Non-Hodgkin Lymphoma | NOT_YET_RECRUITING | NCT07477366 |
| N-803 | Other | Phase PHASE2 | Relapsed B-Cell Non-Hodgkin Lymphoma | NOT_YET_RECRUITING | NCT07477366 |
| CD19 t-haNK- IV Administration | Other | Phase PHASE2 | Relapsed B-Cell Non-Hodgkin Lymphoma | NOT_YET_RECRUITING | NCT07477366 |
| Tumor Biopsy | Other | Phase PHASE1 | Metastatic Urothelial Carcinoma | WITHDRAWN | NCT07217496 |
| Radiographic Imaging | Other | Phase PHASE1 | Metastatic Urothelial Carcinoma | WITHDRAWN | NCT07217496 |
| Research Biospecimen Collection | Other | Phase PHASE1 | Metastatic Urothelial Carcinoma | WITHDRAWN | NCT07217496 |
| Pembrolizumab | Other | Phase PHASE1 | Metastatic Urothelial Carcinoma | WITHDRAWN | NCT07217496 |
| Enfortumab Vedotin (EV) | Other | Phase PHASE1 | Metastatic Urothelial Carcinoma | WITHDRAWN | NCT07217496 |
| Nogapendekin Alfa Inbakicept (N803) | Other | Phase PHASE1 | Metastatic Urothelial Carcinoma | WITHDRAWN | NCT07217496 |
| Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797) | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome | NOT_YET_RECRUITING | NCT07492888 |
| Nogapendekin Alfa-Inbakicept (NAI) | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome | NOT_YET_RECRUITING | NCT07492888 |
| agenT-797 | Other | Phase PHASE3 | Community-Acquired Pneumonia (CAP) | NOT_YET_RECRUITING | NCT07492875 |
| Nogapendekin alfa inbakicept (NAI) | Other | Phase PHASE3 | Community-Acquired Pneumonia (CAP) | NOT_YET_RECRUITING | NCT07492875 |
| N-803 (IL-15 Superagonist) | Other | Phase PHASE2 | Long COVID | RECRUITING | NCT07108036 |
| rMBCG | Other | Preclinical | NMIBC | AVAILABLE | NCT06810141 |
| Intravesical Recombinant Mycobacterium (rMBCG) | Other | Phase PHASE1 | NMIBC | RECRUITING | NCT06800963 |
| BCG (50mg/instillation) | Other | Phase PHASE1 | Non-muscle Invasive Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT02138734 |
| BCG (50mg/instillation) + N-803 (400 μg/instillation) | Other | Phase PHASE1 | Non-muscle Invasive Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT02138734 |
| N803 | Other | Phase PHASE1 | B-cell Non Hodgkin Lymphoma | WITHDRAWN | NCT07049432 |
| CD19 t-haNK | Other | Phase PHASE1 | Non-Hodgkin Lymphoma Refractory/ Relapsed | RECRUITING | NCT06334991 |
| Rituximab | Other | Phase PHASE1 | Non Hodgkin's Lymphoma Refractory/Relapsed | RECRUITING | NCT05618925 |
| Fludarabine | Other | Phase PHASE1 | Non Hodgkin's Lymphoma Refractory/Relapsed | RECRUITING | NCT05618925 |
| Cyclophosphamide | Other | Phase PHASE1 | Non Hodgkin's Lymphoma Refractory/Relapsed | RECRUITING | NCT05618925 |
| CD19t-haNK suspension | Other | Phase PHASE1 | Non Hodgkin's Lymphoma Refractory/Relapsed | RECRUITING | NCT05618925 |
| N803 | Other | Phase PHASE1 | Non Hodgkin's Lymphoma Refractory/Relapsed | RECRUITING | NCT05618925 |
| PD-L1 t-haNK | Other | Phase PHASE1 | Locally Advanced Solid Tumor | COMPLETED | NCT04050709 |
| Nab-paclitaxel | Other | Phase PHASE1 | Advanced Pancreatic Carcinoma | COMPLETED | NCT05304936 |
| Gemcitabine (GEM) | Other | Phase PHASE1 | Advanced Pancreatic Carcinoma | COMPLETED | NCT05304936 |
| HCW9218 | Other | Phase PHASE1 | Advanced Pancreatic Carcinoma | COMPLETED | NCT05304936 |
| NAI + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel | Other | Phase PHASE3 | Non Small Cell Lung Cancer | TERMINATED | NCT03520686 |
| Carboplatin and nab-paclitaxel plus atezolizumab. | Other | Phase PHASE3 | Non Small Cell Lung Cancer | TERMINATED | NCT03520686 |
| Carboplatin and paclitaxel plus atezolizumab and bevacizumab. | Other | Phase PHASE3 | Non Small Cell Lung Cancer | TERMINATED | NCT03520686 |
| Cisplatin/carboplatin and pemetrexed plus atezolizumab. | Other | Phase PHASE3 | Non Small Cell Lung Cancer | TERMINATED | NCT03520686 |
| Cisplatin/carboplatin and pemetrexed plus pembrolizumab. | Other | Phase PHASE3 | Non Small Cell Lung Cancer | TERMINATED | NCT03520686 |
| Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel (Investigator's choice) | Other | Phase PHASE3 | Non Small Cell Lung Cancer | TERMINATED | NCT03520686 |
| NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel | Other | Phase PHASE3 | Non Small Cell Lung Cancer | TERMINATED | NCT03520686 |
| Pembrolizumab | Other | Phase PHASE3 | Non Small Cell Lung Cancer | TERMINATED | NCT03520686 |
| NAI + Nivolumab + Ipilimumab | Other | Phase PHASE3 | Non Small Cell Lung Cancer | TERMINATED | NCT03520686 |
| NAI + Pembrolizumab | Other | Phase PHASE3 | Non Small Cell Lung Cancer | TERMINATED | NCT03520686 |
| CD19 t-haNK | Other | Phase PHASE1 | B-ALL | RECRUITING | NCT07556757 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N803 plus Bacillus Calmette-Guerin (BCG) | Other | Preclinical | Non Muscle Invasive Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT05981131 |
| Nab paclitaxel / gemcitabine | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Zabadinostat (CXD101) | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Sotevtamab | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Nogapendekin Alfa Inbakicept (N803) | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| CD19 t-haNK | Other | Phase PHASE1 | B-ALL | RECRUITING | NCT07556757 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N803 plus Bacillus Calmette-Guerin (BCG) | Other | Preclinical | Non Muscle Invasive Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT05981131 |
| N803 plus Bacillus Calmette-Guerin (BCG) | Other | Preclinical | Non Muscle Invasive Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT05981131 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| CD19 t-haNK | Other | Phase PHASE1 | B-ALL | RECRUITING | NCT07556757 |
| Nab paclitaxel / gemcitabine | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Zabadinostat (CXD101) | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Sotevtamab | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Nogapendekin Alfa Inbakicept (N803) | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| N803 plus Bacillus Calmette-Guerin (BCG) | Other | Preclinical | Non Muscle Invasive Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT05981131 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| CD19 t-haNK | Other | Phase PHASE1 | B-ALL | RECRUITING | NCT07556757 |
| Nab paclitaxel / gemcitabine | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Zabadinostat (CXD101) | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Sotevtamab | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Nogapendekin Alfa Inbakicept (N803) | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| N803 plus Bacillus Calmette-Guerin (BCG) | Other | Preclinical | Non Muscle Invasive Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT05981131 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| CD19 t-haNK | Other | Phase PHASE1 | B-ALL | RECRUITING | NCT07556757 |
| Nab paclitaxel / gemcitabine | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Zabadinostat (CXD101) | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Sotevtamab | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Nogapendekin Alfa Inbakicept (N803) | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| N803 plus Bacillus Calmette-Guerin (BCG) | Other | Preclinical | Non Muscle Invasive Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT05981131 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| CD19 t-haNK | Other | Phase PHASE1 | B-ALL | RECRUITING | NCT07556757 |
| Nab paclitaxel / gemcitabine | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Zabadinostat (CXD101) | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Sotevtamab | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Nogapendekin Alfa Inbakicept (N803) | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| N803 plus Bacillus Calmette-Guerin (BCG) | Other | Preclinical | Non Muscle Invasive Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT05981131 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| CD19 t-haNK | Other | Phase PHASE1 | B-ALL | RECRUITING | NCT07556757 |
| Nab paclitaxel / gemcitabine | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Zabadinostat (CXD101) | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Sotevtamab | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Nogapendekin Alfa Inbakicept (N803) | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| N803 plus Bacillus Calmette-Guerin (BCG) | Other | Preclinical | Non Muscle Invasive Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT05981131 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| CD19 t-haNK | Other | Phase PHASE1 | B-ALL | RECRUITING | NCT07556757 |
| Nab paclitaxel / gemcitabine | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Zabadinostat (CXD101) | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Sotevtamab | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Nogapendekin Alfa Inbakicept (N803) | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| N803 plus Bacillus Calmette-Guerin (BCG) | Other | Preclinical | Non Muscle Invasive Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT05981131 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| CD19 t-haNK | Other | Phase PHASE1 | B-ALL | RECRUITING | NCT07556757 |
| Nab paclitaxel / gemcitabine | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Zabadinostat (CXD101) | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Sotevtamab | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Nogapendekin Alfa Inbakicept (N803) | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| N803 plus Bacillus Calmette-Guerin (BCG) | Other | Preclinical | Non Muscle Invasive Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT05981131 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| CD19 t-haNK | Other | Phase PHASE1 | B-ALL | RECRUITING | NCT07556757 |
| Nab paclitaxel / gemcitabine | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Zabadinostat (CXD101) | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Sotevtamab | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Nogapendekin Alfa Inbakicept (N803) | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| N803 plus Bacillus Calmette-Guerin (BCG) | Other | Preclinical | Non Muscle Invasive Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT05981131 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| CD19 t-haNK | Other | Phase PHASE1 | B-ALL | RECRUITING | NCT07556757 |
| Nab paclitaxel / gemcitabine | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Zabadinostat (CXD101) | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Sotevtamab | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Nogapendekin Alfa Inbakicept (N803) | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| N803 plus Bacillus Calmette-Guerin (BCG) | Other | Preclinical | Non Muscle Invasive Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT05981131 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| CD19 t-haNK | Other | Phase PHASE1 | B-ALL | RECRUITING | NCT07556757 |
| Nab paclitaxel / gemcitabine | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Zabadinostat (CXD101) | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Sotevtamab | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Nogapendekin Alfa Inbakicept (N803) | Other | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| BCG (50 mg) | Other | Phase PHASE3 | NMIBC | NOT_YET_RECRUITING | NCT07551544 |
| BCG (50 mg) plus ANKTIVA (400 µg) | Other | Phase PHASE3 | NMIBC | NOT_YET_RECRUITING | NCT07551544 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| BCG (50 mg) | Other | Phase PHASE3 | NMIBC | NOT_YET_RECRUITING | NCT07551544 |
| BCG (50 mg) plus ANKTIVA (400 µg) | Other | Phase PHASE3 | NMIBC | NOT_YET_RECRUITING | NCT07551544 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| BCG (50 mg) | Other | Phase PHASE3 | NMIBC | NOT_YET_RECRUITING | NCT07551544 |
| BCG (50 mg) plus ANKTIVA (400 µg) | Other | Phase PHASE3 | NMIBC | NOT_YET_RECRUITING | NCT07551544 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| BCG (50 mg) | Other | Phase PHASE3 | NMIBC | NOT_YET_RECRUITING | NCT07551544 |
| BCG (50 mg) plus ANKTIVA (400 µg) | Other | Phase PHASE3 | NMIBC | NOT_YET_RECRUITING | NCT07551544 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| BCG (50 mg) | Other | Phase PHASE3 | NMIBC | NOT_YET_RECRUITING | NCT07551544 |
| BCG (50 mg) plus ANKTIVA (400 µg) | Other | Phase PHASE3 | NMIBC | NOT_YET_RECRUITING | NCT07551544 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| BCG (50 mg) | Other | Phase PHASE3 | NMIBC | NOT_YET_RECRUITING | NCT07551544 |
| BCG (50 mg) plus ANKTIVA (400 µg) | Other | Phase PHASE3 | NMIBC | NOT_YET_RECRUITING | NCT07551544 |
| Prior failed checkpoint inhibitor | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Docetaxel | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| Tislelizumab | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| N-803 | Other | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| BCG (50 mg) | Other | Phase PHASE3 | NMIBC | NOT_YET_RECRUITING | NCT07551544 |
| BCG (50 mg) plus ANKTIVA (400 µg) | Other | Phase PHASE3 | NMIBC | NOT_YET_RECRUITING | NCT07551544 |
| Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797) | DRUG | Phase PHASE2 | Acute Respiratory Distress Syndrome | NOT_YET_RECRUITING | NCT07492888 |
| Nogapendekin Alfa-Inbakicept (NAI) | DRUG | Phase PHASE2 | Acute Respiratory Distress Syndrome | NOT_YET_RECRUITING | NCT07492888 |
| agenT-797 | BIOLOGICAL | Phase PHASE3 | Community-Acquired Pneumonia (CAP) | NOT_YET_RECRUITING | NCT07492875 |
| Nogapendekin alfa inbakicept (NAI) | BIOLOGICAL | Phase PHASE3 | Community-Acquired Pneumonia (CAP) | NOT_YET_RECRUITING | NCT07492875 |
| Nab paclitaxel / gemcitabine | DRUG | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Zabadinostat (CXD101) | DRUG | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Sotevtamab | DRUG | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| Nogapendekin alfa inbakicept | DRUG | Phase PHASE2 | Non-small Cell Lung Cancer Stage IV | NOT_YET_RECRUITING | NCT07355205 |
| Ipilimumab | DRUG | Phase PHASE2 | Non-small Cell Lung Cancer Stage IV | NOT_YET_RECRUITING | NCT07355205 |
| Tumor Biopsy | PROCEDURE | Phase PHASE1 | Metastatic Urothelial Carcinoma | WITHDRAWN | NCT07217496 |
| Radiographic Imaging | PROCEDURE | Phase PHASE1 | Metastatic Urothelial Carcinoma | WITHDRAWN | NCT07217496 |
| Research Biospecimen Collection | PROCEDURE | Phase PHASE1 | Metastatic Urothelial Carcinoma | WITHDRAWN | NCT07217496 |
| Enfortumab Vedotin (EV) | DRUG | Phase PHASE1 | Metastatic Urothelial Carcinoma | WITHDRAWN | NCT07217496 |
| Nogapendekin Alfa Inbakicept (N803) | DRUG | Phase PHASE1 | Pancreatic Cancer Resectable | NOT_YET_RECRUITING | NCT07488884 |
| CD19 t-haNK- IV Administration | BIOLOGICAL | Phase PHASE2 | Relapsed B-Cell Non-Hodgkin Lymphoma | NOT_YET_RECRUITING | NCT07477366 |
| Anktiva | DRUG | Phase PHASE2 | Long COVID | RECRUITING | NCT07123727 |
| nogapendekin-alfa inbakicept | DRUG | Preclinical | Lymphopenia | AVAILABLE | NCT06956547 |
| N-803 and Gemcitabine | DRUG | Phase PHASE2 | Non-muscle Invasive Bladder Cancer (NMIBC) | NOT_YET_RECRUITING | NCT06829823 |
| rMBCG | BIOLOGICAL | Preclinical | NMIBC | AVAILABLE | NCT06810141 |
| Intravesical Recombinant Mycobacterium (rMBCG) | BIOLOGICAL | Phase PHASE1 | NMIBC | RECRUITING | NCT06800963 |
| Post-radiation immunotherapy | RADIATION | Phase PHASE2 | High-risk Prostate Cancer | NOT_YET_RECRUITING | NCT06765954 |
| Androgen Deprivation Therapy (ADT) | RADIATION | Phase PHASE2 | High-risk Prostate Cancer | NOT_YET_RECRUITING | NCT06765954 |
| External Beam Radiation Therapy (EBRT) | RADIATION | Phase PHASE2 | High-risk Prostate Cancer | NOT_YET_RECRUITING | NCT06765954 |
| M-CENK (Activated NK Cells) | DRUG | Phase PHASE2 | High-risk Prostate Cancer | NOT_YET_RECRUITING | NCT06765954 |
| ETBX-071 (PSA-based Oncolytic Virus) | DRUG | Phase PHASE2 | High-risk Prostate Cancer | NOT_YET_RECRUITING | NCT06765954 |
| ETBX-071 | DRUG | Phase PHASE2 | High-risk Prostate Cancer | NOT_YET_RECRUITING | NCT06765902 |
| Tislelizumab | DRUG | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| M-CENK | DRUG | Phase PHASE2 | High-risk Prostate Cancer | NOT_YET_RECRUITING | NCT06765902 |
| Interleukin 2 | DRUG | Phase PHASE1 | Platinum-resistant Ovarian Cancer | RECRUITING | NCT06321484 |
| Cytokine-Induced Memory-like Natural Killer Cells | BIOLOGICAL | Phase PHASE1 | Platinum-resistant Ovarian Cancer | RECRUITING | NCT06321484 |
| NAI | BIOLOGICAL | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT06239220 |
| Tumor Treating Fields (TTFields, 200 kHz) | DEVICE | Phase PHASE2 | Glioblastoma | RECRUITING | NCT06061809 |
| Placebo (0.9% (w/v) saline) | BIOLOGICAL | Phase PHASE2 | COVID-19 | TERMINATED | NCT06022224 |
| hAd5-S-Fusion+N-ETSD | BIOLOGICAL | Phase PHASE2 | COVID-19 | TERMINATED | NCT06022224 |
| N803 plus Bacillus Calmette-Guerin (BCG) | DRUG | Preclinical | Non Muscle Invasive Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT05981131 |
| IBRX-042 | DRUG | Phase PHASE1 | HPV-Related Carcinoma | ACTIVE_NOT_RECRUITING | NCT05976828 |
| Rituximab | DRUG | Phase PHASE1 | Non Hodgkin's Lymphoma Refractory/Relapsed | RECRUITING | NCT05618925 |
| CD19t-haNK suspension | BIOLOGICAL | Phase PHASE1 | Non Hodgkin's Lymphoma Refractory/Relapsed | RECRUITING | NCT05618925 |
| N803 | DRUG | Phase PHASE1 | B-cell Non Hodgkin Lymphoma | WITHDRAWN | NCT07049432 |
| EUA or approved vaccine | BIOLOGICAL | Phase PHASE1 | COVID-19 | TERMINATED | NCT05370040 |
| AAHI-SC3 Vaccine | BIOLOGICAL | Phase PHASE1 | COVID-19 | TERMINATED | NCT05370040 |
| AAHI-SC2 Vaccine | BIOLOGICAL | Phase PHASE1 | COVID-19 | TERMINATED | NCT05370040 |
| HCW9218 | DRUG | Phase PHASE1 | Advanced Pancreatic Carcinoma | COMPLETED | NCT05304936 |
| Sacituzumab Govitecan-Hziy | DRUG | Phase PHASE1 | Advanced Triple Negative Breast Cancer | TERMINATED | NCT04927884 |
| Apheresis collection of MNCs (part A) | OTHER | Phase PHASE1 | Metastatic Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04898543 |
| N-803 (Cohort 2 part B) | BIOLOGICAL | Phase PHASE1 | Metastatic Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04898543 |
| M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B) | BIOLOGICAL | Phase PHASE1 | Metastatic Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04898543 |
| hAd5-SFusion+ N-ETSD (Oral capsule) | DRUG | Phase PHASE1 | Covid19 | TERMINATED | NCT04732468 |
| hAd5-S-Fusion+N-ETSD (Suspension for injection) | BIOLOGICAL | Phase PHASE1 | Covid19 | TERMINATED | NCT04732468 |
| hAd5-S-Fusion+N-ETSD vaccine | BIOLOGICAL | Phase PHASE1 | Covid19 | WITHDRAWN | NCT04845191 |
| Placebo | BIOLOGICAL | Phase PHASE1 | COVID | TERMINATED | NCT04397796 |
| BM-Allo.MSC | BIOLOGICAL | Phase PHASE1 | COVID | TERMINATED | NCT04397796 |
| Irinotecan liposome | DRUG | Phase PHASE2 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04390399 |
| Saline | OTHER | Phase PHASE1 | COVID-19 | TERMINATED | NCT04385849 |
| 10-1074 | BIOLOGICAL | Phase PHASE1 | HIV Infection | ACTIVE_NOT_RECRUITING | NCT04340596 |
| VRC07-523LS | BIOLOGICAL | Phase PHASE1 | HIV Infection | ACTIVE_NOT_RECRUITING | NCT04340596 |
| N-803 (IL-15 Superagonist) | DRUG | Phase PHASE2 | Long COVID | RECRUITING | NCT07108036 |
| CD19 t-haNK | BIOLOGICAL | Phase PHASE1 | Non-Hodgkin Lymphoma Refractory/ Relapsed | RECRUITING | NCT06334991 |
| PD-L1 t-haNK | BIOLOGICAL | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT06239220 |
| haNK™ | BIOLOGICAL | Phase PHASE2 | Merkel Cell Carcinoma | TERMINATED | NCT03853317 |
| carboplatin | DRUG | Phase PHASE2 | Non Small Cell Lung Cancer | WITHDRAWN | NCT03574649 |
| Docetaxel | DRUG | Phase PHASE3 | NSCLC Stage IV | RECRUITING | NCT06745908 |
| 5Fluorouracil | DRUG | Phase PHASE2 | Non Small Cell Lung Cancer | WITHDRAWN | NCT03574649 |
| Aldoxorubicin hydrochloride | BIOLOGICAL | Phase PHASE1 | Hepatocellular Carcinoma Non-resectable | WITHDRAWN | NCT03563170 |
| Sorafenib | DRUG | Phase PHASE1 | Hepatocellular Carcinoma Non-resectable | WITHDRAWN | NCT03563170 |
| Regorafenib | DRUG | Phase PHASE1 | Colorectal Cancer Metastatic | TERMINATED | NCT03563157 |
| Aldoxorubicin Hydrochloride | BIOLOGICAL | Phase PHASE1 | Chordoma | WITHDRAWN | NCT03647423 |
| Nab-paclitaxel | DRUG | Phase PHASE2 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04390399 |
| Gemcitabine | DRUG | Phase PHASE2 | Platinum-resistant Ovarian Cancer | RECRUITING | NCT06710288 |
| paclitaxel | DRUG | Phase PHASE2 | Triple Negative Breast Cancer (TNBC) | WITHDRAWN | NCT03554109 |
| Doxorubicin HCL | DRUG | Phase PHASE2 | Triple Negative Breast Cancer (TNBC) | WITHDRAWN | NCT03554109 |
| NAI + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel | DRUG | Phase PHASE3 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03520686 |
| Carboplatin and nab-paclitaxel plus atezolizumab. | DRUG | Phase PHASE3 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03520686 |
| Carboplatin and paclitaxel plus atezolizumab and bevacizumab. | DRUG | Phase PHASE3 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03520686 |
| Cisplatin/carboplatin and pemetrexed plus atezolizumab. | DRUG | Phase PHASE3 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03520686 |
| Cisplatin/carboplatin and pemetrexed plus pembrolizumab. | DRUG | Phase PHASE3 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03520686 |
| Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel (Investigator's choice) | DRUG | Phase PHASE3 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03520686 |
| NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel | DRUG | Phase PHASE3 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03520686 |
| Pembrolizumab | DRUG | Phase PHASE1 | Metastatic Urothelial Carcinoma | WITHDRAWN | NCT07217496 |
| NAI + Nivolumab + Ipilimumab | DRUG | Phase PHASE3 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03520686 |
| NAI + Pembrolizumab | DRUG | Phase PHASE3 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03520686 |
| Necitumumab | DRUG | Phase PHASE1 | Squamous Cell Carcinoma | TERMINATED | NCT03387111 |
| haNK for Infusion | BIOLOGICAL | Phase PHASE1 | Triple Negative Breast Cancer | TERMINATED | NCT03387085 |
| Aldoxorubicin HCl | DRUG | Phase PHASE2 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04390399 |
| SBRT | PROCEDURE | Phase PHASE2 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04390399 |
| lovaza | DRUG | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03387098 |
| Fluorouracil | DRUG | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03586869 |
| haNK for infusion | BIOLOGICAL | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03586869 |
| N-803 + Docetaxel + Nivolumab | DRUG | Phase PHASE2 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03228667 |
| N-803 + Docetaxel + Pembrolizumab | DRUG | Phase PHASE2 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03228667 |
| N-803 + Durvalumab + PD-L1 t-haNK | DRUG | Phase PHASE2 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03228667 |
| N-803 + Avelumab + PD-L1 t-haNK | DRUG | Phase PHASE2 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03228667 |
| N-803 + Atezolizumab + PD-L1 t-haNK | DRUG | Phase PHASE2 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03228667 |
| N-803 + Nivolumab + PD-L1 t-haNK | DRUG | Phase PHASE2 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03228667 |
| N-803 + Pembrolizumab + PD-L1 t-haNK | DRUG | Phase PHASE2 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03228667 |
| N-803 + Durvalumab | DRUG | Phase PHASE2 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03228667 |
| N-803 + Avelumab | DRUG | Phase PHASE2 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03228667 |
| N-803 + Atezolizumab | DRUG | Phase PHASE2 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03228667 |
| N-803 + Nivolumab | DRUG | Phase PHASE2 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03228667 |
| N-803 + Pembrolizumab | DRUG | Phase PHASE2 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT03228667 |
| haNK® | BIOLOGICAL | Phase PHASE1 | Ovarian Cancer | WITHDRAWN | NCT03197584 |
| omega-3 acid ethyl esters | DRUG | Phase PHASE1 | Ovarian Cancer | WITHDRAWN | NCT03197584 |
| Paclitaxel | DRUG | Phase PHASE1 | Ovarian Cancer | WITHDRAWN | NCT03197584 |
| Fulvestrant | DRUG | Phase PHASE1 | Ovarian Cancer | WITHDRAWN | NCT03197584 |
| 5Fluorouracil (5-FU) | DRUG | Phase PHASE1 | Urothelial Carcinoma | WITHDRAWN | NCT03197571 |
| cisplatin | DRUG | Phase PHASE1 | Urothelial Carcinoma | WITHDRAWN | NCT03197571 |
| rituximab | DRUG | Phase PHASE2 | Relapsed B-Cell Non-Hodgkin Lymphoma | NOT_YET_RECRUITING | NCT07477366 |
| oxaliplatin | DRUG | Phase PHASE1 | Colorectal Cancer | WITHDRAWN | NCT03169777 |
| cetuximab | BIOLOGICAL | Phase PHASE1 | Colorectal Cancer | WITHDRAWN | NCT03169777 |
| capecitabine | DRUG | Phase PHASE1 | Urothelial Carcinoma | WITHDRAWN | NCT03197571 |
| Cetuximab | DRUG | Phase PHASE2 | Head and Neck Cancer | RECRUITING | NCT06239220 |
| ETBX-021 | BIOLOGICAL | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03586869 |
| Lovaza | DRUG | Phase PHASE1 | Urothelial Carcinoma | WITHDRAWN | NCT03197571 |
| nivolumab | BIOLOGICAL | Phase PHASE1 | Colorectal Cancer | WITHDRAWN | NCT03169777 |
| nab paclitaxel | DRUG | Phase PHASE1 | Colorectal Cancer | WITHDRAWN | NCT03169777 |
| leucovorin | DRUG | Phase PHASE1 | Urothelial Carcinoma | WITHDRAWN | NCT03197571 |
| fulvestrant | DRUG | Phase PHASE1 | Urothelial Carcinoma | WITHDRAWN | NCT03197571 |
| 5-Fluorouracil (5-FU) | DRUG | Phase PHASE1 | Non Hodgkin Lymphoma | WITHDRAWN | NCT03169790 |
| cyclophosphamide | DRUG | Phase PHASE1 | Urothelial Carcinoma | WITHDRAWN | NCT03197571 |
| GI-6207 | BIOLOGICAL | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03586869 |
| Nivolumab | DRUG | Phase PHASE2 | Non-small Cell Lung Cancer Stage IV | NOT_YET_RECRUITING | NCT07355205 |
| haNK | BIOLOGICAL | Phase PHASE1 | Chordoma | WITHDRAWN | NCT03647423 |
| GI-6301 | BIOLOGICAL | Phase PHASE1 | Chordoma | WITHDRAWN | NCT03647423 |
| ETBX-061 | BIOLOGICAL | Phase PHASE1 | Chordoma | WITHDRAWN | NCT03647423 |
| ETBX-051 | BIOLOGICAL | Phase PHASE1 | Chordoma | WITHDRAWN | NCT03647423 |
| Stereotactic Body Radiation Therapy | RADIATION | Phase PHASE1 | Ovarian Cancer | WITHDRAWN | NCT03197584 |
| omega-3-acid ethyl esters | DRUG | Phase PHASE1 | Melanoma | WITHDRAWN | NCT03167177 |
| nab-Paclitaxel | DRUG | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03586869 |
| 5-fluorouracil | DRUG | Phase PHASE1 | Ovarian Cancer | WITHDRAWN | NCT03197584 |
| Cisplatin | DRUG | Phase PHASE2 | Non Small Cell Lung Cancer | WITHDRAWN | NCT03574649 |
| Bevacizumab | DRUG | Phase PHASE2 | Glioblastoma | RECRUITING | NCT06061809 |
| Avelumab | BIOLOGICAL | Phase PHASE2 | Merkel Cell Carcinoma | TERMINATED | NCT03853317 |
| GI-4000 | BIOLOGICAL | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03586869 |
| ETBX-011 | BIOLOGICAL | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03586869 |
| aNK for Infusion | BIOLOGICAL | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03136406 |
| avelumab | BIOLOGICAL | Phase PHASE1 | Hepatocellular Carcinoma Non-resectable | WITHDRAWN | NCT03563170 |
| bevacizumab | BIOLOGICAL | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03586869 |
| nab-paclitaxel | DRUG | Phase PHASE1 | Urothelial Carcinoma | WITHDRAWN | NCT03197571 |
| Leucovorin | DRUG | Phase PHASE2 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04390399 |
| 5-Fluorouracil | DRUG | Phase PHASE2 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT04390399 |
| Capecitabine | DRUG | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03586869 |
| Oxaliplatin | DRUG | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT03586869 |
| haNK™ for Infusion | BIOLOGICAL | Phase PHASE1 | Solid Tumor | COMPLETED | NCT03027128 |
| N-803 | DRUG | Phase PHASE2 | Relapsed B-Cell Non-Hodgkin Lymphoma | NOT_YET_RECRUITING | NCT07477366 |
| N-803 and BCG | DRUG | Phase PHASE2 | Non-muscle Invasive Bladder Cancer (NMIBC) | NOT_YET_RECRUITING | NCT06829823 |
| CIML NK cell infusion | PROCEDURE | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT02782546 |
| G-CSF | DRUG | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT02782546 |
| Mycophenolate mofetil | DRUG | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT02782546 |
| Tacrolimus | DRUG | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT02782546 |
| Graft cell infusion | PROCEDURE | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT02782546 |
| aNK (NK-92) + N-803 | BIOLOGICAL | Phase PHASE2 | Stage IIIB Merkel Cell Carcinoma | TERMINATED | NCT02465957 |
| aNK (NK-92) | BIOLOGICAL | Phase PHASE2 | Stage IIIB Merkel Cell Carcinoma | TERMINATED | NCT02465957 |
| Topotecan | DRUG | Phase PHASE2 | Metastatic Small Cell Lung Cancer | COMPLETED | NCT02200757 |
| 170 mg/m2 aldoxorubicin | DRUG | Phase PHASE1 | Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma | COMPLETED | NCT02235701 |
| gemcitabine | DRUG | Phase PHASE1 | Metastatic Solid Tumors | COMPLETED | NCT02235688 |
| BCG (50mg/instillation) | BIOLOGICAL | Phase PHASE1 | Non-muscle Invasive Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT02138734 |
| BCG (50mg/instillation) + N-803 (400 μg/instillation) | BIOLOGICAL | Phase PHASE1 | Non-muscle Invasive Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT02138734 |
| Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide) | DRUG | Phase PHASE3 | Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma | COMPLETED | NCT02049905 |
| Aldoxorubicin | DRUG | Phase PHASE2 | Non Small Cell Lung Cancer | WITHDRAWN | NCT03574649 |
| 150 mg/m2 aldoxorubicin | DRUG | Phase PHASE2 | Kaposi's Sarcoma | COMPLETED | NCT02029430 |
| 100 mg/m2 aldoxorubicin | DRUG | Phase PHASE2 | Kaposi's Sarcoma | COMPLETED | NCT02029430 |
| 50 mg/m2 aldoxorubicin | DRUG | Phase PHASE2 | Kaposi's Sarcoma | COMPLETED | NCT02029430 |
| 350 mg/m2 aldoxorubicin | DRUG | Phase PHASE2 | Glioblastoma | COMPLETED | NCT02014844 |
| 250 mg/m2 aldoxorubicin | DRUG | Phase PHASE1 | Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma | COMPLETED | NCT02235701 |
| Bone marrow for correlative studies | PROCEDURE | Phase PHASE1 | Leukemia, Myeloid, Acute | TERMINATED | NCT01898793 |
| Peripheral blood for correlative studies | PROCEDURE | Phase PHASE1 | Leukemia, Myeloid, Acute | TERMINATED | NCT01898793 |
| ALT-803 | BIOLOGICAL | Phase PHASE1 | Chordoma | WITHDRAWN | NCT03647423 |
| IL-2 | BIOLOGICAL | Phase PHASE1 | Leukemia, Myeloid, Acute | TERMINATED | NCT01898793 |
| Cytokine-induced killer cells | BIOLOGICAL | Phase PHASE1 | Leukemia, Myeloid, Acute | TERMINATED | NCT01898793 |
| Leukapheresis | PROCEDURE | Phase PHASE2 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT02782546 |
| Cyclophosphamide | DRUG | Phase PHASE1 | Non Hodgkin's Lymphoma Refractory/Relapsed | RECRUITING | NCT05618925 |
| Fludarabine | DRUG | Phase PHASE1 | Non Hodgkin's Lymphoma Refractory/Relapsed | RECRUITING | NCT05618925 |
| aldoxorubicin | DRUG | Phase PHASE1 | Metastatic Solid Tumors | COMPLETED | NCT02235688 |
| Doxorubicin | DRUG | Phase PHASE2 | Metastatic Soft Tissue Sarcoma | COMPLETED | NCT01514188 |
| INNO-206 | DRUG | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma | COMPLETED | NCT01580397 |
| Neukoplast™ (NK-92) | BIOLOGICAL | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT00900809 |
Total products: 1186